id	sid	tid	token	lemma	pos
dpc-3893	1	1	dermatology	dermatology	NOUN
dpc-3893	1	2	:	:	PUNCT
dpc-3893	1	3	practical	practical	ADJ
dpc-3893	1	4	and	and	CCONJ
dpc-3893	1	5	conceptual	conceptual	ADJ
dpc-3893	1	6	review	review	NOUN
dpc-3893	1	7	|	|	ADV
dpc-3893	1	8	dermatol	dermatol	ADJ
dpc-3893	1	9	pract	pract	NOUN
dpc-3893	1	10	concept	concept	NOUN
dpc-3893	1	11	.	.	PUNCT
dpc-3893	2	1	2023;13(4)s2	2023;13(4)s2	NOUN
dpc-3893	2	2	:	:	PUNCT
dpc-3893	2	3	e2023313s	e2023313s	PROPN
dpc-3893	2	4	1	1	NUM
dpc-3893	2	5	vitiligo	vitiligo	NOUN
dpc-3893	2	6	:	:	PUNCT
dpc-3893	2	7	current	current	ADJ
dpc-3893	2	8	therapies	therapy	NOUN
dpc-3893	2	9	and	and	CCONJ
dpc-3893	2	10	future	future	ADJ
dpc-3893	2	11	treatments	treatment	NOUN
dpc-3893	2	12	julien	julien	PROPN
dpc-3893	2	13	seneschal1,2	seneschal1,2	PROPN
dpc-3893	2	14	,	,	PUNCT
dpc-3893	2	15	katia	katia	PROPN
dpc-3893	2	16	boniface2	boniface2	PROPN
dpc-3893	2	17	1	1	NUM
dpc-3893	2	18	department	department	NOUN
dpc-3893	2	19	of	of	ADP
dpc-3893	2	20	dermatology	dermatology	NOUN
dpc-3893	2	21	and	and	CCONJ
dpc-3893	2	22	pediatric	pediatric	ADJ
dpc-3893	2	23	dermatology	dermatology	NOUN
dpc-3893	2	24	,	,	PUNCT
dpc-3893	2	25	national	national	ADJ
dpc-3893	2	26	reference	reference	NOUN
dpc-3893	2	27	center	center	NOUN
dpc-3893	2	28	for	for	ADP
dpc-3893	2	29	rare	rare	ADJ
dpc-3893	2	30	skin	skin	NOUN
dpc-3893	2	31	disorders	disorder	NOUN
dpc-3893	2	32	,	,	PUNCT
dpc-3893	2	33	hôpital	hôpital	ADJ
dpc-3893	2	34	saint	saint	PROPN
dpc-3893	2	35	-	-	PUNCT
dpc-3893	2	36	andré	andré	VERB
dpc-3893	2	37	,	,	PUNCT
dpc-3893	2	38	bordeaux	bordeaux	NOUN
dpc-3893	2	39	,	,	PUNCT
dpc-3893	2	40	france	france	PROPN
dpc-3893	2	41	2	2	NUM
dpc-3893	2	42	university	university	NOUN
dpc-3893	2	43	of	of	ADP
dpc-3893	2	44	bordeaux	bordeaux	NOUN
dpc-3893	2	45	,	,	PUNCT
dpc-3893	2	46	cnrs	cnrs	NOUN
dpc-3893	2	47	,	,	PUNCT
dpc-3893	2	48	immuno	immuno	ADJ
dpc-3893	2	49	concept	concept	NOUN
dpc-3893	2	50	,	,	PUNCT
dpc-3893	2	51	umr	umr	PROPN
dpc-3893	2	52	5164	5164	NUM
dpc-3893	2	53	,	,	PUNCT
dpc-3893	2	54	bordeaux	bordeaux	NOUN
dpc-3893	2	55	,	,	PUNCT
dpc-3893	2	56	france	france	PROPN
dpc-3893	2	57	key	key	ADJ
dpc-3893	2	58	words	word	NOUN
dpc-3893	2	59	:	:	PUNCT
dpc-3893	2	60	vitiligo	vitiligo	NOUN
dpc-3893	2	61	,	,	PUNCT
dpc-3893	2	62	management	management	NOUN
dpc-3893	2	63	,	,	PUNCT
dpc-3893	2	64	treatment	treatment	NOUN
dpc-3893	2	65	citation	citation	NOUN
dpc-3893	2	66	:	:	PUNCT
dpc-3893	2	67	seneschal	seneschal	PROPN
dpc-3893	2	68	j	j	PROPN
dpc-3893	2	69	,	,	PUNCT
dpc-3893	2	70	boniface	boniface	PROPN
dpc-3893	2	71	k.	k.	PROPN
dpc-3893	2	72	vitiligo	vitiligo	PROPN
dpc-3893	2	73	:	:	PUNCT
dpc-3893	2	74	current	current	ADJ
dpc-3893	2	75	therapies	therapy	NOUN
dpc-3893	2	76	and	and	CCONJ
dpc-3893	2	77	future	future	ADJ
dpc-3893	2	78	treatments	treatment	NOUN
dpc-3893	2	79	.	.	PUNCT
dpc-3893	3	1	dermatol	dermatol	NOUN
dpc-3893	3	2	pract	pract	PROPN
dpc-3893	3	3	concept	concept	NOUN
dpc-3893	3	4	.	.	PUNCT
dpc-3893	4	1	2023;13(4)s2	2023;13(4)s2	NOUN
dpc-3893	4	2	:	:	PUNCT
dpc-3893	4	3	e2023313s	e2023313s	PROPN
dpc-3893	4	4	.	.	PUNCT
dpc-3893	4	5	doi	doi	PROPN
dpc-3893	4	6	:	:	PUNCT
dpc-3893	4	7	https://doi.org/10.5826/dpc.1304s2a313s	https://doi.org/10.5826/dpc.1304s2a313s	PROPN
dpc-3893	4	8	accepted	accept	VERB
dpc-3893	4	9	:	:	PUNCT
dpc-3893	4	10	december	december	PROPN
dpc-3893	4	11	13	13	NUM
dpc-3893	4	12	,	,	PUNCT
dpc-3893	4	13	2023	2023	NUM
dpc-3893	4	14	;	;	PUNCT
dpc-3893	4	15	published	publish	VERB
dpc-3893	4	16	:	:	PUNCT
dpc-3893	5	1	december	december	PROPN
dpc-3893	5	2	2023	2023	NUM
dpc-3893	5	3	copyright	copyright	NOUN
dpc-3893	5	4	:	:	PUNCT
dpc-3893	5	5	©	©	PROPN
dpc-3893	5	6	2023	2023	NUM
dpc-3893	5	7	seneschal	seneschal	NOUN
dpc-3893	5	8	et	et	PROPN
dpc-3893	5	9	al	al	PROPN
dpc-3893	5	10	.	.	PUNCT
dpc-3893	6	1	this	this	PRON
dpc-3893	6	2	is	be	AUX
dpc-3893	6	3	an	an	DET
dpc-3893	6	4	open	open	ADJ
dpc-3893	6	5	-	-	PUNCT
dpc-3893	6	6	access	access	NOUN
dpc-3893	6	7	article	article	NOUN
dpc-3893	6	8	distributed	distribute	VERB
dpc-3893	6	9	under	under	ADP
dpc-3893	6	10	the	the	DET
dpc-3893	6	11	terms	term	NOUN
dpc-3893	6	12	of	of	ADP
dpc-3893	6	13	the	the	DET
dpc-3893	6	14	creative	creative	ADJ
dpc-3893	6	15	commons	common	NOUN
dpc-3893	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3893	6	17	license	license	NOUN
dpc-3893	6	18	(	(	PUNCT
dpc-3893	6	19	by	by	ADP
dpc-3893	6	20	-	-	PUNCT
dpc-3893	6	21	nc-4.0	nc-4.0	NOUN
dpc-3893	6	22	)	)	PUNCT
dpc-3893	6	23	,	,	PUNCT
dpc-3893	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3893	6	25	,	,	PUNCT
dpc-3893	6	26	which	which	PRON
dpc-3893	6	27	permits	permit	VERB
dpc-3893	6	28	unrestricted	unrestricted	ADJ
dpc-3893	6	29	noncommercial	noncommercial	ADJ
dpc-3893	6	30	use	use	NOUN
dpc-3893	6	31	,	,	PUNCT
dpc-3893	6	32	distribution	distribution	NOUN
dpc-3893	6	33	,	,	PUNCT
dpc-3893	6	34	and	and	CCONJ
dpc-3893	6	35	reproduction	reproduction	NOUN
dpc-3893	6	36	in	in	ADP
dpc-3893	6	37	any	any	DET
dpc-3893	6	38	medium	medium	NOUN
dpc-3893	6	39	,	,	PUNCT
dpc-3893	6	40	provided	provide	VERB
dpc-3893	6	41	the	the	DET
dpc-3893	6	42	original	original	ADJ
dpc-3893	6	43	authors	author	NOUN
dpc-3893	6	44	and	and	CCONJ
dpc-3893	6	45	source	source	NOUN
dpc-3893	6	46	are	be	AUX
dpc-3893	6	47	credited	credit	VERB
dpc-3893	6	48	.	.	PUNCT
dpc-3893	7	1	funding	funding	NOUN
dpc-3893	7	2	:	:	PUNCT
dpc-3893	7	3	none	none	NOUN
dpc-3893	7	4	.	.	PUNCT
dpc-3893	8	1	competing	compete	VERB
dpc-3893	8	2	interests	interest	NOUN
dpc-3893	8	3	:	:	PUNCT
dpc-3893	8	4	julien	julien	PROPN
dpc-3893	8	5	seneschal	seneschal	PROPN
dpc-3893	8	6	:	:	PUNCT
dpc-3893	8	7	received	receive	VERB
dpc-3893	8	8	grants	grant	NOUN
dpc-3893	8	9	and/or	and/or	CCONJ
dpc-3893	8	10	honoraria	honorarium	NOUN
dpc-3893	8	11	from	from	ADP
dpc-3893	8	12	abbvie	abbvie	PROPN
dpc-3893	8	13	,	,	PUNCT
dpc-3893	8	14	bristol	bristol	PROPN
dpc-3893	8	15	myers	myers	PROPN
dpc-3893	8	16	squibb	squibb	PROPN
dpc-3893	8	17	,	,	PUNCT
dpc-3893	8	18	calypso	calypso	PROPN
dpc-3893	8	19	biotech	biotech	NOUN
dpc-3893	8	20	,	,	PUNCT
dpc-3893	8	21	eli	eli	PROPN
dpc-3893	8	22	lilly	lilly	PROPN
dpc-3893	8	23	,	,	PUNCT
dpc-3893	8	24	incyte	incyte	PROPN
dpc-3893	8	25	,	,	PUNCT
dpc-3893	8	26	leo	leo	PROPN
dpc-3893	8	27	pharma	pharma	PROPN
dpc-3893	8	28	,	,	PUNCT
dpc-3893	8	29	novartis	novartis	NOUN
dpc-3893	8	30	,	,	PUNCT
dpc-3893	8	31	pfizer	pfizer	NOUN
dpc-3893	8	32	,	,	PUNCT
dpc-3893	8	33	pierre	pierre	PROPN
dpc-3893	8	34	fabre	fabre	PROPN
dpc-3893	8	35	,	,	PUNCT
dpc-3893	8	36	sanofi	sanofi	PROPN
dpc-3893	8	37	,	,	PUNCT
dpc-3893	8	38	sun	sun	NOUN
dpc-3893	8	39	pharmaceuticals	pharmaceutical	NOUN
dpc-3893	8	40	,	,	PUNCT
dpc-3893	8	41	and	and	CCONJ
dpc-3893	8	42	viela	viela	PROPN
dpc-3893	8	43	bio	bio	PROPN
dpc-3893	8	44	;	;	PUNCT
dpc-3893	8	45	and	and	CCONJ
dpc-3893	8	46	has	have	VERB
dpc-3893	8	47	a	a	DET
dpc-3893	8	48	patent	patent	NOUN
dpc-3893	8	49	on	on	ADP
dpc-3893	8	50	mmp9	mmp9	ADJ
dpc-3893	8	51	inhibitors	inhibitor	NOUN
dpc-3893	8	52	and	and	CCONJ
dpc-3893	8	53	uses	use	VERB
dpc-3893	8	54	thereof	thereof	ADV
dpc-3893	8	55	in	in	ADP
dpc-3893	8	56	the	the	DET
dpc-3893	8	57	prevention	prevention	NOUN
dpc-3893	8	58	or	or	CCONJ
dpc-3893	8	59	treatment	treatment	NOUN
dpc-3893	8	60	of	of	ADP
dpc-3893	8	61	a	a	DET
dpc-3893	8	62	depigmenting	depigmente	VERB
dpc-3893	8	63	disorder	disorder	NOUN
dpc-3893	8	64	and	and	CCONJ
dpc-3893	8	65	three	three	NUM
dpc-3893	8	66	-	-	PUNCT
dpc-3893	8	67	dimensional	dimensional	ADJ
dpc-3893	8	68	model	model	NOUN
dpc-3893	8	69	of	of	ADP
dpc-3893	8	70	depigmenting	depigmente	VERB
dpc-3893	8	71	disorder	disorder	NOUN
dpc-3893	8	72	.	.	PUNCT
dpc-3893	9	1	katia	katia	PROPN
dpc-3893	9	2	boniface	boniface	PROPN
dpc-3893	9	3	:	:	PUNCT
dpc-3893	9	4	received	receive	VERB
dpc-3893	9	5	grants	grant	NOUN
dpc-3893	9	6	from	from	ADP
dpc-3893	9	7	calypso	calypso	PROPN
dpc-3893	9	8	biotech	biotech	NOUN
dpc-3893	9	9	,	,	PUNCT
dpc-3893	9	10	leo	leo	PROPN
dpc-3893	9	11	pharma	pharma	PROPN
dpc-3893	9	12	,	,	PUNCT
dpc-3893	9	13	pfizer	pfizer	NOUN
dpc-3893	9	14	,	,	PUNCT
dpc-3893	9	15	pierre	pierre	PROPN
dpc-3893	9	16	fabre	fabre	PROPN
dpc-3893	9	17	,	,	PUNCT
dpc-3893	9	18	sanofi	sanofi	PROPN
dpc-3893	9	19	,	,	PUNCT
dpc-3893	9	20	and	and	CCONJ
dpc-3893	9	21	has	have	VERB
dpc-3893	9	22	a	a	DET
dpc-3893	9	23	patent	patent	NOUN
dpc-3893	9	24	on	on	ADP
dpc-3893	9	25	mmp9	mmp9	ADJ
dpc-3893	9	26	inhibitors	inhibitor	NOUN
dpc-3893	9	27	and	and	CCONJ
dpc-3893	9	28	uses	use	VERB
dpc-3893	9	29	thereof	thereof	ADV
dpc-3893	9	30	in	in	ADP
dpc-3893	9	31	the	the	DET
dpc-3893	9	32	prevention	prevention	NOUN
dpc-3893	9	33	or	or	CCONJ
dpc-3893	9	34	treatment	treatment	NOUN
dpc-3893	9	35	of	of	ADP
dpc-3893	9	36	a	a	DET
dpc-3893	9	37	depigmenting	depigmente	VERB
dpc-3893	9	38	disorder	disorder	NOUN
dpc-3893	9	39	and	and	CCONJ
dpc-3893	9	40	three	three	NUM
dpc-3893	9	41	-	-	PUNCT
dpc-3893	9	42	dimensional	dimensional	ADJ
dpc-3893	9	43	model	model	NOUN
dpc-3893	9	44	of	of	ADP
dpc-3893	9	45	depigmenting	depigmente	VERB
dpc-3893	9	46	disorder	disorder	NOUN
dpc-3893	9	47	.	.	PUNCT
dpc-3893	10	1	authorship	authorship	NOUN
dpc-3893	10	2	:	:	PUNCT
dpc-3893	10	3	both	both	CCONJ
dpc-3893	10	4	the	the	DET
dpc-3893	10	5	authors	author	NOUN
dpc-3893	10	6	have	have	AUX
dpc-3893	10	7	contributed	contribute	VERB
dpc-3893	10	8	significantly	significantly	ADV
dpc-3893	10	9	to	to	ADP
dpc-3893	10	10	this	this	DET
dpc-3893	10	11	publication	publication	NOUN
dpc-3893	10	12	.	.	PUNCT
dpc-3893	11	1	corresponding	correspond	VERB
dpc-3893	11	2	author	author	NOUN
dpc-3893	11	3	:	:	PUNCT
dpc-3893	11	4	julien	julien	PROPN
dpc-3893	11	5	seneschal	seneschal	PROPN
dpc-3893	11	6	,	,	PUNCT
dpc-3893	11	7	department	department	NOUN
dpc-3893	11	8	of	of	ADP
dpc-3893	11	9	dermatology	dermatology	NOUN
dpc-3893	11	10	,	,	PUNCT
dpc-3893	11	11	hôpital	hôpital	PROPN
dpc-3893	11	12	saint	saint	PROPN
dpc-3893	11	13	-	-	PUNCT
dpc-3893	11	14	andré	andré	PROPN
dpc-3893	11	15	,	,	PUNCT
dpc-3893	11	16	chu	chu	PROPN
dpc-3893	11	17	de	de	X
dpc-3893	11	18	bordeaux	bordeaux	PROPN
dpc-3893	11	19	,	,	PUNCT
dpc-3893	11	20	bordeaux	bordeaux	NOUN
dpc-3893	11	21	,	,	PUNCT
dpc-3893	11	22	france	france	PROPN
dpc-3893	11	23	.	.	PUNCT
dpc-3893	12	1	bordeaux	bordeaux	PROPN
dpc-3893	12	2	university	university	PROPN
dpc-3893	12	3	,	,	PUNCT
dpc-3893	12	4	cnrs	cnrs	NOUN
dpc-3893	12	5	,	,	PUNCT
dpc-3893	12	6	immunoconcept	immunoconcept	NOUN
dpc-3893	12	7	,	,	PUNCT
dpc-3893	12	8	umr	umr	PROPN
dpc-3893	12	9	5164	5164	NUM
dpc-3893	12	10	,	,	PUNCT
dpc-3893	12	11	33000	33000	NUM
dpc-3893	12	12	bordeaux	bordeaux	NOUN
dpc-3893	12	13	,	,	PUNCT
dpc-3893	12	14	france	france	PROPN
dpc-3893	12	15	.	.	PUNCT
dpc-3893	13	1	phone	phone	NOUN
dpc-3893	13	2	 	 	SPACE
dpc-3893	13	3	:	:	PUNCT
dpc-3893	13	4	+33(0)5	+33(0)5	PROPN
dpc-3893	13	5	56	56	NUM
dpc-3893	13	6	79	79	NUM
dpc-3893	13	7	47	47	NUM
dpc-3893	13	8	05	05	NUM
dpc-3893	13	9	fax	fax	NOUN
dpc-3893	13	10	 	 	SPACE
dpc-3893	13	11	:	:	PUNCT
dpc-3893	13	12	+33(0)5	+33(0)5	PROPN
dpc-3893	13	13	56	56	NUM
dpc-3893	13	14	79	79	NUM
dpc-3893	13	15	49	49	NUM
dpc-3893	13	16	75	75	NUM
dpc-3893	13	17	e	e	NOUN
dpc-3893	13	18	-	-	NOUN
dpc-3893	13	19	mail	mail	NOUN
dpc-3893	13	20	:	:	PUNCT
dpc-3893	13	21	julien.seneschal@chu-bordeaux.fr	julien.seneschal@chu-bordeaux.fr	VERB
dpc-3893	13	22	the	the	DET
dpc-3893	13	23	current	current	ADJ
dpc-3893	13	24	management	management	NOUN
dpc-3893	13	25	of	of	ADP
dpc-3893	13	26	vitiligo	vitiligo	NOUN
dpc-3893	13	27	remains	remain	VERB
dpc-3893	13	28	challenging	challenging	ADJ
dpc-3893	13	29	;	;	PUNCT
dpc-3893	13	30	however	however	ADV
dpc-3893	13	31	,	,	PUNCT
dpc-3893	13	32	different	different	ADJ
dpc-3893	13	33	strategies	strategy	NOUN
dpc-3893	13	34	can	can	AUX
dpc-3893	13	35	be	be	AUX
dpc-3893	13	36	proposed	propose	VERB
dpc-3893	13	37	to	to	ADP
dpc-3893	13	38	patients	patient	NOUN
dpc-3893	13	39	with	with	ADP
dpc-3893	13	40	a	a	DET
dpc-3893	13	41	good	good	ADJ
dpc-3893	13	42	efficacy	efficacy	NOUN
dpc-3893	13	43	in	in	ADP
dpc-3893	13	44	many	many	ADJ
dpc-3893	13	45	cases	case	NOUN
dpc-3893	13	46	.	.	PUNCT
dpc-3893	14	1	first	first	ADV
dpc-3893	14	2	,	,	PUNCT
dpc-3893	14	3	it	it	PRON
dpc-3893	14	4	is	be	AUX
dpc-3893	14	5	important	important	ADJ
dpc-3893	14	6	to	to	PART
dpc-3893	14	7	identify	identify	VERB
dpc-3893	14	8	patients	patient	NOUN
dpc-3893	14	9	in	in	ADP
dpc-3893	14	10	the	the	DET
dpc-3893	14	11	active	active	ADJ
dpc-3893	14	12	phase	phase	NOUN
dpc-3893	14	13	of	of	ADP
dpc-3893	14	14	the	the	DET
dpc-3893	14	15	disease	disease	NOUN
dpc-3893	14	16	because	because	SCONJ
dpc-3893	14	17	treatment	treatment	NOUN
dpc-3893	14	18	should	should	AUX
dpc-3893	14	19	start	start	VERB
dpc-3893	14	20	as	as	ADV
dpc-3893	14	21	soon	soon	ADV
dpc-3893	14	22	as	as	ADP
dpc-3893	14	23	possible	possible	ADJ
dpc-3893	14	24	to	to	PART
dpc-3893	14	25	halt	halt	VERB
dpc-3893	14	26	its	its	PRON
dpc-3893	14	27	progression	progression	NOUN
dpc-3893	14	28	.	.	PUNCT
dpc-3893	15	1	for	for	ADP
dpc-3893	15	2	patients	patient	NOUN
dpc-3893	15	3	with	with	ADP
dpc-3893	15	4	a	a	DET
dpc-3893	15	5	stable	stable	ADJ
dpc-3893	15	6	disease	disease	NOUN
dpc-3893	15	7	,	,	PUNCT
dpc-3893	15	8	the	the	DET
dpc-3893	15	9	treatment	treatment	NOUN
dpc-3893	15	10	strategy	strategy	NOUN
dpc-3893	15	11	is	be	AUX
dpc-3893	15	12	now	now	ADV
dpc-3893	15	13	well	well	ADV
dpc-3893	15	14	-	-	PUNCT
dpc-3893	15	15	stratified	stratify	VERB
dpc-3893	15	16	and	and	CCONJ
dpc-3893	15	17	is	be	AUX
dpc-3893	15	18	based	base	VERB
dpc-3893	15	19	on	on	ADP
dpc-3893	15	20	a	a	DET
dpc-3893	15	21	combination	combination	NOUN
dpc-3893	15	22	of	of	ADP
dpc-3893	15	23	phototherapy	phototherapy	NOUN
dpc-3893	15	24	(	(	PUNCT
dpc-3893	15	25	natural	natural	ADJ
dpc-3893	15	26	or	or	CCONJ
dpc-3893	15	27	in	in	ADP
dpc-3893	15	28	a	a	DET
dpc-3893	15	29	cabin	cabin	NOUN
dpc-3893	15	30	)	)	PUNCT
dpc-3893	15	31	and	and	CCONJ
dpc-3893	15	32	topical	topical	ADJ
dpc-3893	15	33	immunomodulatory	immunomodulatory	ADJ
dpc-3893	15	34	agents	agent	NOUN
dpc-3893	15	35	.	.	PUNCT
dpc-3893	16	1	surgical	surgical	ADJ
dpc-3893	16	2	treatments	treatment	NOUN
dpc-3893	16	3	are	be	AUX
dpc-3893	16	4	useful	useful	ADJ
dpc-3893	16	5	for	for	ADP
dpc-3893	16	6	localized	localized	ADJ
dpc-3893	16	7	and	and	CCONJ
dpc-3893	16	8	stable	stable	ADJ
dpc-3893	16	9	vitiligo	vitiligo	NOUN
dpc-3893	16	10	,	,	PUNCT
dpc-3893	16	11	as	as	ADV
dpc-3893	16	12	well	well	ADV
dpc-3893	16	13	as	as	ADP
dpc-3893	16	14	for	for	ADP
dpc-3893	16	15	segmental	segmental	ADJ
dpc-3893	16	16	vitiligo	vitiligo	NOUN
dpc-3893	16	17	.	.	PUNCT
dpc-3893	17	1	depigmentation	depigmentation	NOUN
dpc-3893	17	2	remains	remain	VERB
dpc-3893	17	3	indicated	indicate	VERB
dpc-3893	17	4	in	in	ADP
dpc-3893	17	5	very	very	ADV
dpc-3893	17	6	extensive	extensive	ADJ
dpc-3893	17	7	forms	form	NOUN
dpc-3893	17	8	.	.	PUNCT
dpc-3893	18	1	the	the	DET
dpc-3893	18	2	recent	recent	ADJ
dpc-3893	18	3	approval	approval	NOUN
dpc-3893	18	4	of	of	ADP
dpc-3893	18	5	topical	topical	ADJ
dpc-3893	18	6	ruxolitinib	ruxolitinib	NOUN
dpc-3893	18	7	cream	cream	NOUN
dpc-3893	18	8	in	in	ADP
dpc-3893	18	9	both	both	CCONJ
dpc-3893	18	10	the	the	DET
dpc-3893	18	11	us	us	PROPN
dpc-3893	18	12	and	and	CCONJ
dpc-3893	18	13	europe	europe	PROPN
dpc-3893	18	14	brings	bring	VERB
dpc-3893	18	15	new	new	ADJ
dpc-3893	18	16	approaches	approach	NOUN
dpc-3893	18	17	for	for	ADP
dpc-3893	18	18	the	the	DET
dpc-3893	18	19	management	management	NOUN
dpc-3893	18	20	of	of	ADP
dpc-3893	18	21	vitiligo	vitiligo	NOUN
dpc-3893	18	22	and	and	CCONJ
dpc-3893	18	23	paves	pave	VERB
dpc-3893	18	24	the	the	DET
dpc-3893	18	25	way	way	NOUN
dpc-3893	18	26	for	for	ADP
dpc-3893	18	27	the	the	DET
dpc-3893	18	28	development	development	NOUN
dpc-3893	18	29	of	of	ADP
dpc-3893	18	30	new	new	ADJ
dpc-3893	18	31	topical	topical	ADJ
dpc-3893	18	32	or	or	CCONJ
dpc-3893	18	33	oral	oral	ADJ
dpc-3893	18	34	targeted	target	VERB
dpc-3893	18	35	drugs	drug	NOUN
dpc-3893	18	36	.	.	PUNCT
dpc-3893	19	1	abstract	abstract	ADJ
dpc-3893	19	2	introduction	introduction	NOUN
dpc-3893	19	3	vitiligo	vitiligo	NOUN
dpc-3893	19	4	is	be	AUX
dpc-3893	19	5	a	a	DET
dpc-3893	19	6	common	common	ADJ
dpc-3893	19	7	chronic	chronic	NOUN
dpc-3893	19	8	depigmenting	depigmente	VERB
dpc-3893	19	9	skin	skin	NOUN
dpc-3893	19	10	disease	disease	NOUN
dpc-3893	19	11	that	that	PRON
dpc-3893	19	12	can	can	AUX
dpc-3893	19	13	have	have	VERB
dpc-3893	19	14	a	a	DET
dpc-3893	19	15	significant	significant	ADJ
dpc-3893	19	16	impact	impact	NOUN
dpc-3893	19	17	on	on	ADP
dpc-3893	19	18	the	the	DET
dpc-3893	19	19	quality	quality	NOUN
dpc-3893	19	20	of	of	ADP
dpc-3893	19	21	life	life	NOUN
dpc-3893	19	22	of	of	ADP
dpc-3893	19	23	those	those	PRON
dpc-3893	19	24	affected	affect	VERB
dpc-3893	19	25	.	.	PUNCT
dpc-3893	20	1	consequently	consequently	ADV
dpc-3893	20	2	,	,	PUNCT
dpc-3893	20	3	there	there	PRON
dpc-3893	20	4	is	be	VERB
dpc-3893	20	5	often	often	ADV
dpc-3893	20	6	a	a	DET
dpc-3893	20	7	high	high	ADJ
dpc-3893	20	8	demand	demand	NOUN
dpc-3893	20	9	for	for	ADP
dpc-3893	20	10	treatment	treatment	NOUN
dpc-3893	20	11	among	among	ADP
dpc-3893	20	12	patients	patient	NOUN
dpc-3893	20	13	.	.	PUNCT
dpc-3893	21	1	advances	advance	NOUN
dpc-3893	21	2	in	in	ADP
dpc-3893	21	3	understanding	understand	VERB
dpc-3893	21	4	the	the	DET
dpc-3893	21	5	pathomechanisms	pathomechanism	NOUN
dpc-3893	21	6	of	of	ADP
dpc-3893	21	7	vitiligo	vitiligo	NOUN
dpc-3893	21	8	led	lead	VERB
dpc-3893	21	9	to	to	ADP
dpc-3893	21	10	the	the	DET
dpc-3893	21	11	development	development	NOUN
dpc-3893	21	12	of	of	ADP
dpc-3893	21	13	targeted	target	VERB
dpc-3893	21	14	therapies	therapy	NOUN
dpc-3893	21	15	.	.	PUNCT
dpc-3893	22	1	for	for	ADP
dpc-3893	22	2	example	example	NOUN
dpc-3893	22	3	,	,	PUNCT
dpc-3893	22	4	ruxolitinib	ruxolitinib	NOUN
dpc-3893	22	5	,	,	PUNCT
dpc-3893	22	6	a	a	DET
dpc-3893	22	7	topical	topical	ADJ
dpc-3893	22	8	jak1/	jak1/	PROPN
dpc-3893	22	9	jak2	jak2	PROPN
dpc-3893	22	10	inhibitor	inhibitor	NOUN
dpc-3893	22	11	,	,	PUNCT
dpc-3893	22	12	is	be	AUX
dpc-3893	22	13	now	now	ADV
dpc-3893	22	14	approved	approve	VERB
dpc-3893	22	15	for	for	ADP
dpc-3893	22	16	the	the	DET
dpc-3893	22	17	management	management	NOUN
dpc-3893	22	18	of	of	ADP
dpc-3893	22	19	vitiligo	vitiligo	NOUN
dpc-3893	22	20	both	both	PRON
dpc-3893	22	21	in	in	ADP
dpc-3893	22	22	the	the	DET
dpc-3893	22	23	us	us	PROPN
dpc-3893	22	24	and	and	CCONJ
dpc-3893	22	25	europe	europe	PROPN
dpc-3893	22	26	.	.	PUNCT
dpc-3893	23	1	this	this	DET
dpc-3893	23	2	review	review	NOUN
dpc-3893	23	3	aims	aim	VERB
dpc-3893	23	4	to	to	PART
dpc-3893	23	5	provide	provide	VERB
dpc-3893	23	6	2	2	NUM
dpc-3893	23	7	review	review	NOUN
dpc-3893	23	8	|	|	ADV
dpc-3893	23	9	dermatol	dermatol	ADJ
dpc-3893	23	10	pract	pract	NOUN
dpc-3893	23	11	concept	concept	NOUN
dpc-3893	23	12	.	.	PUNCT
dpc-3893	24	1	2023;13(4)s2	2023;13(4)s2	NOUN
dpc-3893	24	2	:	:	PUNCT
dpc-3893	24	3	e2023313s	e2023313s	X
dpc-3893	24	4	a	a	DET
dpc-3893	24	5	practical	practical	ADJ
dpc-3893	24	6	guidance	guidance	NOUN
dpc-3893	24	7	on	on	ADP
dpc-3893	24	8	managing	manage	VERB
dpc-3893	24	9	patients	patient	NOUN
dpc-3893	24	10	with	with	ADP
dpc-3893	24	11	vitiligo	vitiligo	NOUN
dpc-3893	24	12	and	and	CCONJ
dpc-3893	24	13	to	to	PART
dpc-3893	24	14	explore	explore	VERB
dpc-3893	24	15	potential	potential	ADJ
dpc-3893	24	16	future	future	ADJ
dpc-3893	24	17	therapies	therapy	NOUN
dpc-3893	24	18	currently	currently	ADV
dpc-3893	24	19	in	in	ADP
dpc-3893	24	20	development	development	NOUN
dpc-3893	24	21	.	.	PUNCT
dpc-3893	25	1	recent	recent	ADJ
dpc-3893	25	2	worldwide	worldwide	ADJ
dpc-3893	25	3	expert	expert	ADJ
dpc-3893	25	4	recommendations	recommendation	NOUN
dpc-3893	25	5	for	for	ADP
dpc-3893	25	6	the	the	DET
dpc-3893	25	7	diagnosis	diagnosis	NOUN
dpc-3893	25	8	and	and	CCONJ
dpc-3893	25	9	management	management	NOUN
dpc-3893	25	10	of	of	ADP
dpc-3893	25	11	vitiligo	vitiligo	NOUN
dpc-3893	25	12	have	have	AUX
dpc-3893	25	13	been	be	AUX
dpc-3893	25	14	recently	recently	ADV
dpc-3893	25	15	published	publish	VERB
dpc-3893	25	16	[	[	PUNCT
dpc-3893	25	17	1,2	1,2	NUM
dpc-3893	25	18	]	]	PUNCT
dpc-3893	25	19	.	.	PUNCT
dpc-3893	26	1	part	part	NOUN
dpc-3893	26	2	1	1	NUM
dpc-3893	26	3	of	of	ADP
dpc-3893	26	4	the	the	DET
dpc-3893	26	5	recommendations	recommendation	NOUN
dpc-3893	26	6	provides	provide	VERB
dpc-3893	26	7	a	a	DET
dpc-3893	26	8	practical	practical	ADJ
dpc-3893	26	9	algorithm	algorithm	NOUN
dpc-3893	26	10	for	for	ADP
dpc-3893	26	11	the	the	DET
dpc-3893	26	12	treatment	treatment	NOUN
dpc-3893	26	13	of	of	ADP
dpc-3893	26	14	vitiligo	vitiligo	NOUN
dpc-3893	26	15	.	.	PUNCT
dpc-3893	27	1	objectives	objective	NOUN
dpc-3893	27	2	of	of	ADP
dpc-3893	27	3	treatments	treatment	NOUN
dpc-3893	27	4	treatment	treatment	NOUN
dpc-3893	27	5	strategies	strategy	NOUN
dpc-3893	27	6	depend	depend	VERB
dpc-3893	27	7	on	on	ADP
dpc-3893	27	8	several	several	ADJ
dpc-3893	27	9	clinical	clinical	ADJ
dpc-3893	27	10	characteristics	characteristic	NOUN
dpc-3893	27	11	,	,	PUNCT
dpc-3893	27	12	such	such	ADJ
dpc-3893	27	13	as	as	ADP
dpc-3893	27	14	disease	disease	NOUN
dpc-3893	27	15	subtype	subtype	NOUN
dpc-3893	27	16	,	,	PUNCT
dpc-3893	27	17	the	the	DET
dpc-3893	27	18	extent	extent	NOUN
dpc-3893	27	19	of	of	ADP
dpc-3893	27	20	vitiligo	vitiligo	NOUN
dpc-3893	27	21	,	,	PUNCT
dpc-3893	27	22	and	and	CCONJ
dpc-3893	27	23	disease	disease	NOUN
dpc-3893	27	24	activity	activity	NOUN
dpc-3893	27	25	.	.	PUNCT
dpc-3893	28	1	these	these	DET
dpc-3893	28	2	factors	factor	NOUN
dpc-3893	28	3	should	should	AUX
dpc-3893	28	4	be	be	AUX
dpc-3893	28	5	systematically	systematically	ADV
dpc-3893	28	6	assessed	assess	VERB
dpc-3893	28	7	before	before	ADP
dpc-3893	28	8	deciding	decide	VERB
dpc-3893	28	9	on	on	ADP
dpc-3893	28	10	a	a	DET
dpc-3893	28	11	specific	specific	ADJ
dpc-3893	28	12	therapy	therapy	NOUN
dpc-3893	28	13	.	.	PUNCT
dpc-3893	29	1	the	the	DET
dpc-3893	29	2	management	management	NOUN
dpc-3893	29	3	of	of	ADP
dpc-3893	29	4	vitiligo	vitiligo	NOUN
dpc-3893	29	5	should	should	AUX
dpc-3893	29	6	encompass	encompass	VERB
dpc-3893	29	7	three	three	NUM
dpc-3893	29	8	main	main	ADJ
dpc-3893	29	9	complementary	complementary	ADJ
dpc-3893	29	10	objectives	objective	NOUN
dpc-3893	29	11	:	:	PUNCT
dpc-3893	29	12	1	1	X
dpc-3893	29	13	)	)	PUNCT
dpc-3893	29	14	halting	halting	ADJ
dpc-3893	29	15	disease	disease	NOUN
dpc-3893	29	16	progression	progression	NOUN
dpc-3893	29	17	,	,	PUNCT
dpc-3893	29	18	2	2	X
dpc-3893	29	19	)	)	PUNCT
dpc-3893	29	20	inducing	induce	VERB
dpc-3893	29	21	repigmentation	repigmentation	NOUN
dpc-3893	29	22	,	,	PUNCT
dpc-3893	29	23	melanocyte	melanocyte	NOUN
dpc-3893	29	24	regeneration	regeneration	NOUN
dpc-3893	29	25	and	and	CCONJ
dpc-3893	29	26	proliferation	proliferation	NOUN
dpc-3893	29	27	,	,	PUNCT
dpc-3893	29	28	and	and	CCONJ
dpc-3893	29	29	3	3	X
dpc-3893	29	30	)	)	PUNCT
dpc-3893	29	31	maintaining	maintain	VERB
dpc-3893	29	32	repigmentation	repigmentation	NOUN
dpc-3893	29	33	and	and	CCONJ
dpc-3893	29	34	preventing	prevent	VERB
dpc-3893	29	35	disease	disease	NOUN
dpc-3893	29	36	recurrence	recurrence	NOUN
dpc-3893	29	37	.	.	PUNCT
dpc-3893	30	1	treating	treat	VERB
dpc-3893	30	2	patients	patient	NOUN
dpc-3893	30	3	with	with	ADP
dpc-3893	30	4	active	active	ADJ
dpc-3893	30	5	disease	disease	NOUN
dpc-3893	30	6	vitiligo	vitiligo	NOUN
dpc-3893	30	7	is	be	AUX
dpc-3893	30	8	a	a	DET
dpc-3893	30	9	chronic	chronic	ADJ
dpc-3893	30	10	condition	condition	NOUN
dpc-3893	30	11	that	that	PRON
dpc-3893	30	12	often	often	ADV
dpc-3893	30	13	progresses	progress	VERB
dpc-3893	30	14	in	in	ADP
dpc-3893	30	15	flareups	flareup	NOUN
dpc-3893	30	16	.	.	PUNCT
dpc-3893	31	1	it	it	PRON
dpc-3893	31	2	is	be	AUX
dpc-3893	31	3	impossible	impossible	ADJ
dpc-3893	31	4	to	to	PART
dpc-3893	31	5	predict	predict	VERB
dpc-3893	31	6	the	the	DET
dpc-3893	31	7	long	long	ADJ
dpc-3893	31	8	-	-	PUNCT
dpc-3893	31	9	term	term	NOUN
dpc-3893	31	10	evolution	evolution	NOUN
dpc-3893	31	11	of	of	ADP
dpc-3893	31	12	vitiligo	vitiligo	NOUN
dpc-3893	31	13	,	,	PUNCT
dpc-3893	31	14	and	and	CCONJ
dpc-3893	31	15	to	to	ADP
dpc-3893	31	16	date	date	NOUN
dpc-3893	31	17	there	there	PRON
dpc-3893	31	18	are	be	VERB
dpc-3893	31	19	no	no	DET
dpc-3893	31	20	reliable	reliable	ADJ
dpc-3893	31	21	biological	biological	ADJ
dpc-3893	31	22	markers	marker	NOUN
dpc-3893	31	23	of	of	ADP
dpc-3893	31	24	activity	activity	NOUN
dpc-3893	31	25	.	.	PUNCT
dpc-3893	32	1	however	however	ADV
dpc-3893	32	2	,	,	PUNCT
dpc-3893	32	3	clinical	clinical	ADJ
dpc-3893	32	4	signs	sign	NOUN
dpc-3893	32	5	of	of	ADP
dpc-3893	32	6	disease	disease	NOUN
dpc-3893	32	7	activity	activity	NOUN
dpc-3893	32	8	have	have	AUX
dpc-3893	32	9	been	be	AUX
dpc-3893	32	10	identified	identify	VERB
dpc-3893	32	11	,	,	PUNCT
dpc-3893	32	12	such	such	ADJ
dpc-3893	32	13	as	as	ADP
dpc-3893	32	14	inflammatory	inflammatory	ADJ
dpc-3893	32	15	borders	border	NOUN
dpc-3893	32	16	,	,	PUNCT
dpc-3893	32	17	the	the	DET
dpc-3893	32	18	koebner	koebner	NOUN
dpc-3893	32	19	phenomenon	phenomenon	NOUN
dpc-3893	32	20	,	,	PUNCT
dpc-3893	32	21	hypochromic	hypochromic	ADJ
dpc-3893	32	22	areas	area	NOUN
dpc-3893	32	23	/	/	SYM
dpc-3893	32	24	borders	border	NOUN
dpc-3893	32	25	,	,	PUNCT
dpc-3893	32	26	and	and	CCONJ
dpc-3893	32	27	confetti	confetti	NOUN
dpc-3893	32	28	-	-	PUNCT
dpc-3893	32	29	like	like	ADJ
dpc-3893	32	30	depigmentation	depigmentation	NOUN
dpc-3893	32	31	.	.	PUNCT
dpc-3893	33	1	it	it	PRON
dpc-3893	33	2	is	be	AUX
dpc-3893	33	3	essential	essential	ADJ
dpc-3893	33	4	to	to	PART
dpc-3893	33	5	detect	detect	VERB
dpc-3893	33	6	active	active	ADJ
dpc-3893	33	7	forms	form	NOUN
dpc-3893	33	8	of	of	ADP
dpc-3893	33	9	vitiligo	vitiligo	NOUN
dpc-3893	33	10	because	because	SCONJ
dpc-3893	33	11	a	a	DET
dpc-3893	33	12	treatment	treatment	NOUN
dpc-3893	33	13	aiming	aim	VERB
dpc-3893	33	14	to	to	PART
dpc-3893	33	15	block	block	VERB
dpc-3893	33	16	flare	flare	NOUN
dpc-3893	33	17	-	-	PUNCT
dpc-3893	33	18	ups	up	NOUN
dpc-3893	33	19	must	must	AUX
dpc-3893	33	20	be	be	AUX
dpc-3893	33	21	initiated	initiate	VERB
dpc-3893	33	22	urgently	urgently	ADV
dpc-3893	33	23	[	[	X
dpc-3893	33	24	3–7	3–7	NOUN
dpc-3893	33	25	]	]	PUNCT
dpc-3893	33	26	.	.	PUNCT
dpc-3893	34	1	while	while	SCONJ
dpc-3893	34	2	data	datum	NOUN
dpc-3893	34	3	are	be	AUX
dpc-3893	34	4	primarily	primarily	ADV
dpc-3893	34	5	based	base	VERB
dpc-3893	34	6	on	on	ADP
dpc-3893	34	7	open	open	ADJ
dpc-3893	34	8	or	or	CCONJ
dpc-3893	34	9	retrospective	retrospective	ADJ
dpc-3893	34	10	studies	study	NOUN
dpc-3893	34	11	,	,	PUNCT
dpc-3893	34	12	it	it	PRON
dpc-3893	34	13	is	be	AUX
dpc-3893	34	14	now	now	ADV
dpc-3893	34	15	widely	widely	ADV
dpc-3893	34	16	accepted	accept	VERB
dpc-3893	34	17	that	that	SCONJ
dpc-3893	34	18	the	the	DET
dpc-3893	34	19	treatment	treatment	NOUN
dpc-3893	34	20	for	for	ADP
dpc-3893	34	21	patients	patient	NOUN
dpc-3893	34	22	with	with	ADP
dpc-3893	34	23	highly	highly	ADV
dpc-3893	34	24	progressive	progressive	ADJ
dpc-3893	34	25	disease	disease	NOUN
dpc-3893	34	26	should	should	AUX
dpc-3893	34	27	combine	combine	VERB
dpc-3893	34	28	systemic	systemic	ADJ
dpc-3893	34	29	therapies	therapy	NOUN
dpc-3893	34	30	and	and	CCONJ
dpc-3893	34	31	phototherapy	phototherapy	NOUN
dpc-3893	35	1	[	[	X
dpc-3893	35	2	8	8	NUM
dpc-3893	35	3	]	]	PUNCT
dpc-3893	35	4	.	.	PUNCT
dpc-3893	36	1	to	to	ADP
dpc-3893	36	2	date	date	NOUN
dpc-3893	36	3	,	,	PUNCT
dpc-3893	36	4	the	the	DET
dpc-3893	36	5	systemic	systemic	ADJ
dpc-3893	36	6	therapy	therapy	NOUN
dpc-3893	36	7	mainly	mainly	ADV
dpc-3893	36	8	relies	rely	VERB
dpc-3893	36	9	on	on	ADP
dpc-3893	36	10	mini	mini	NOUN
dpc-3893	36	11	-	-	NOUN
dpc-3893	36	12	pulses	pulse	NOUN
dpc-3893	36	13	of	of	ADP
dpc-3893	36	14	systemic	systemic	ADJ
dpc-3893	36	15	steroids	steroid	NOUN
dpc-3893	36	16	for	for	ADP
dpc-3893	36	17	3	3	NUM
dpc-3893	36	18	to	to	PART
dpc-3893	36	19	6	6	NUM
dpc-3893	36	20	months	month	NOUN
dpc-3893	36	21	(	(	PUNCT
dpc-3893	36	22	e.g	e.g	X
dpc-3893	36	23	methylprednisolone	methylprednisolone	NOUN
dpc-3893	36	24	16	16	NUM
dpc-3893	36	25	mg	mg	NOUN
dpc-3893	36	26	(	(	PUNCT
dpc-3893	36	27	or	or	CCONJ
dpc-3893	36	28	dexamethasone	dexamethasone	NOUN
dpc-3893	36	29	5	5	NUM
dpc-3893	36	30	mg	mg	NOUN
dpc-3893	36	31	)	)	PUNCT
dpc-3893	36	32	two	two	NUM
dpc-3893	36	33	consecutive	consecutive	ADJ
dpc-3893	36	34	days	day	NOUN
dpc-3893	36	35	in	in	ADP
dpc-3893	36	36	adults	adult	NOUN
dpc-3893	36	37	,	,	PUNCT
dpc-3893	36	38	the	the	DET
dpc-3893	36	39	dose	dose	NOUN
dpc-3893	36	40	should	should	AUX
dpc-3893	36	41	be	be	AUX
dpc-3893	36	42	adapted	adapt	VERB
dpc-3893	36	43	for	for	ADP
dpc-3893	36	44	children	child	NOUN
dpc-3893	36	45	)	)	PUNCT
dpc-3893	37	1	[	[	X
dpc-3893	37	2	9	9	NUM
dpc-3893	37	3	]	]	PUNCT
dpc-3893	37	4	.	.	PUNCT
dpc-3893	38	1	for	for	ADP
dpc-3893	38	2	children	child	NOUN
dpc-3893	38	3	in	in	ADP
dpc-3893	38	4	the	the	DET
dpc-3893	38	5	growth	growth	NOUN
dpc-3893	38	6	phase	phase	NOUN
dpc-3893	38	7	,	,	PUNCT
dpc-3893	38	8	a	a	DET
dpc-3893	38	9	paediatric	paediatric	ADJ
dpc-3893	38	10	advice	advice	NOUN
dpc-3893	38	11	should	should	AUX
dpc-3893	38	12	be	be	AUX
dpc-3893	38	13	given	give	VERB
dpc-3893	38	14	after	after	ADP
dpc-3893	38	15	3	3	NUM
dpc-3893	38	16	months	month	NOUN
dpc-3893	38	17	of	of	ADP
dpc-3893	38	18	treatment	treatment	NOUN
dpc-3893	38	19	.	.	PUNCT
dpc-3893	39	1	systemic	systemic	ADJ
dpc-3893	39	2	steroids	steroid	NOUN
dpc-3893	39	3	should	should	AUX
dpc-3893	39	4	be	be	AUX
dpc-3893	39	5	combined	combine	VERB
dpc-3893	39	6	with	with	ADP
dpc-3893	39	7	phototherapy	phototherapy	NOUN
dpc-3893	39	8	:	:	PUNCT
dpc-3893	39	9	e.g	e.g	PRON
dpc-3893	39	10	narrow	narrow	ADJ
dpc-3893	39	11	band	band	NOUN
dpc-3893	39	12	uvb	uvb	ADJ
dpc-3893	39	13	2	2	NUM
dpc-3893	39	14	-	-	SYM
dpc-3893	39	15	3	3	NUM
dpc-3893	39	16	times	time	NOUN
dpc-3893	39	17	/	/	SYM
dpc-3893	39	18	week	week	NOUN
dpc-3893	39	19	for	for	ADP
dpc-3893	39	20	6	6	NUM
dpc-3893	39	21	months	month	NOUN
dpc-3893	39	22	.	.	PUNCT
dpc-3893	40	1	this	this	DET
dpc-3893	40	2	combination	combination	NOUN
dpc-3893	40	3	blocks	block	VERB
dpc-3893	40	4	relapses	relapse	NOUN
dpc-3893	40	5	in	in	ADP
dpc-3893	40	6	over	over	ADP
dpc-3893	40	7	80	80	NUM
dpc-3893	40	8	%	%	NOUN
dpc-3893	40	9	of	of	ADP
dpc-3893	40	10	cases	case	NOUN
dpc-3893	40	11	.	.	PUNCT
dpc-3893	41	1	in	in	ADP
dpc-3893	41	2	small	small	ADJ
dpc-3893	41	3	children	child	NOUN
dpc-3893	41	4	,	,	PUNCT
dpc-3893	41	5	phototherapy	phototherapy	NOUN
dpc-3893	41	6	can	can	AUX
dpc-3893	41	7	not	not	PART
dpc-3893	41	8	be	be	AUX
dpc-3893	41	9	used	use	VERB
dpc-3893	41	10	and	and	CCONJ
dpc-3893	41	11	the	the	DET
dpc-3893	41	12	minipulses	minipulse	NOUN
dpc-3893	41	13	are	be	AUX
dpc-3893	41	14	used	use	VERB
dpc-3893	41	15	as	as	ADP
dpc-3893	41	16	a	a	DET
dpc-3893	41	17	monotherapy	monotherapy	NOUN
dpc-3893	41	18	.	.	PUNCT
dpc-3893	42	1	depending	depend	VERB
dpc-3893	42	2	on	on	ADP
dpc-3893	42	3	the	the	DET
dpc-3893	42	4	season	season	NOUN
dpc-3893	42	5	,	,	PUNCT
dpc-3893	42	6	moderate	moderate	ADJ
dpc-3893	42	7	but	but	CCONJ
dpc-3893	42	8	regular	regular	ADJ
dpc-3893	42	9	exposure	exposure	NOUN
dpc-3893	42	10	to	to	ADP
dpc-3893	42	11	the	the	DET
dpc-3893	42	12	sun	sun	NOUN
dpc-3893	42	13	is	be	AUX
dpc-3893	42	14	recommended	recommend	VERB
dpc-3893	42	15	to	to	PART
dpc-3893	42	16	stimulate	stimulate	VERB
dpc-3893	42	17	repigmentation	repigmentation	NOUN
dpc-3893	42	18	.	.	PUNCT
dpc-3893	43	1	treatment	treatment	NOUN
dpc-3893	43	2	for	for	ADP
dpc-3893	43	3	patients	patient	NOUN
dpc-3893	43	4	with	with	ADP
dpc-3893	43	5	a	a	DET
dpc-3893	43	6	stable	stable	ADJ
dpc-3893	43	7	disease	disease	NOUN
dpc-3893	43	8	with	with	ADP
dpc-3893	43	9	current	current	ADJ
dpc-3893	43	10	strategies	strategy	NOUN
dpc-3893	43	11	,	,	PUNCT
dpc-3893	43	12	complete	complete	ADJ
dpc-3893	43	13	or	or	CCONJ
dpc-3893	43	14	near	near	ADP
dpc-3893	43	15	complete	complete	ADJ
dpc-3893	43	16	repigmentation	repigmentation	NOUN
dpc-3893	43	17	could	could	AUX
dpc-3893	43	18	be	be	AUX
dpc-3893	43	19	achieved	achieve	VERB
dpc-3893	43	20	(	(	PUNCT
dpc-3893	43	21	e.g.	e.g.	ADV
dpc-3893	43	22	70	70	NUM
dpc-3893	43	23	to	to	PART
dpc-3893	43	24	80	80	NUM
dpc-3893	43	25	%	%	NOUN
dpc-3893	43	26	of	of	ADP
dpc-3893	43	27	repigmentation	repigmentation	NOUN
dpc-3893	43	28	of	of	ADP
dpc-3893	43	29	lesions	lesion	NOUN
dpc-3893	43	30	located	locate	VERB
dpc-3893	43	31	on	on	ADP
dpc-3893	43	32	the	the	DET
dpc-3893	43	33	face	face	NOUN
dpc-3893	43	34	;	;	PUNCT
dpc-3893	43	35	50	50	NUM
dpc-3893	43	36	%	%	NOUN
dpc-3893	43	37	of	of	ADP
dpc-3893	43	38	repigmentation	repigmentation	NOUN
dpc-3893	43	39	of	of	ADP
dpc-3893	43	40	lesions	lesion	NOUN
dpc-3893	43	41	located	locate	VERB
dpc-3893	43	42	on	on	ADP
dpc-3893	43	43	the	the	DET
dpc-3893	43	44	body	body	NOUN
dpc-3893	43	45	;	;	PUNCT
dpc-3893	43	46	hands	hand	NOUN
dpc-3893	43	47	and/or	and/or	CCONJ
dpc-3893	43	48	feet	foot	NOUN
dpc-3893	43	49	remain	remain	VERB
dpc-3893	43	50	difficult	difficult	ADJ
dpc-3893	43	51	to	to	PART
dpc-3893	43	52	treat	treat	VERB
dpc-3893	43	53	)	)	PUNCT
dpc-3893	43	54	.	.	PUNCT
dpc-3893	44	1	importantly	importantly	ADV
dpc-3893	44	2	,	,	PUNCT
dpc-3893	44	3	the	the	DET
dpc-3893	44	4	treatment	treatment	NOUN
dpc-3893	44	5	should	should	AUX
dpc-3893	44	6	be	be	AUX
dpc-3893	44	7	evaluated	evaluate	VERB
dpc-3893	44	8	after	after	ADP
dpc-3893	44	9	at	at	ADV
dpc-3893	44	10	least	least	ADV
dpc-3893	44	11	6	6	NUM
dpc-3893	44	12	months	month	NOUN
dpc-3893	44	13	.	.	PUNCT
dpc-3893	45	1	indeed	indeed	ADV
dpc-3893	45	2	,	,	PUNCT
dpc-3893	45	3	it	it	PRON
dpc-3893	45	4	can	can	AUX
dpc-3893	45	5	take	take	VERB
dpc-3893	45	6	between	between	ADP
dpc-3893	45	7	6	6	NUM
dpc-3893	45	8	 	 	SPACE
dpc-3893	45	9	to	to	PART
dpc-3893	45	10	24	24	NUM
dpc-3893	45	11	 	 	SPACE
dpc-3893	45	12	months	month	NOUN
dpc-3893	45	13	of	of	ADP
dpc-3893	45	14	treatment	treatment	NOUN
dpc-3893	45	15	to	to	PART
dpc-3893	45	16	achieve	achieve	VERB
dpc-3893	45	17	significant	significant	ADJ
dpc-3893	45	18	repigmentation	repigmentation	NOUN
dpc-3893	45	19	.	.	PUNCT
dpc-3893	46	1	patients	patient	NOUN
dpc-3893	46	2	must	must	AUX
dpc-3893	46	3	be	be	AUX
dpc-3893	46	4	clearly	clearly	ADV
dpc-3893	46	5	warned	warn	VERB
dpc-3893	46	6	that	that	SCONJ
dpc-3893	46	7	the	the	DET
dpc-3893	46	8	treatment	treatment	NOUN
dpc-3893	46	9	is	be	AUX
dpc-3893	46	10	long	long	ADJ
dpc-3893	46	11	and	and	CCONJ
dpc-3893	46	12	often	often	ADV
dpc-3893	46	13	tedious	tedious	ADJ
dpc-3893	46	14	,	,	PUNCT
dpc-3893	46	15	as	as	SCONJ
dpc-3893	46	16	many	many	ADJ
dpc-3893	46	17	patients	patient	NOUN
dpc-3893	46	18	stop	stop	VERB
dpc-3893	46	19	the	the	DET
dpc-3893	46	20	treatment	treatment	NOUN
dpc-3893	46	21	after	after	ADP
dpc-3893	46	22	1	1	NUM
dpc-3893	46	23	to	to	PART
dpc-3893	46	24	2	2	NUM
dpc-3893	46	25	months	month	NOUN
dpc-3893	46	26	without	without	ADP
dpc-3893	46	27	seeing	see	VERB
dpc-3893	46	28	any	any	DET
dpc-3893	46	29	results	result	NOUN
dpc-3893	46	30	.	.	PUNCT
dpc-3893	47	1	topical	topical	ADJ
dpc-3893	47	2	immunomodulatory	immunomodulatory	ADJ
dpc-3893	47	3	treatments	treatment	NOUN
dpc-3893	47	4	are	be	AUX
dpc-3893	47	5	important	important	ADJ
dpc-3893	47	6	.	.	PUNCT
dpc-3893	48	1	on	on	ADP
dpc-3893	48	2	the	the	DET
dpc-3893	48	3	face	face	NOUN
dpc-3893	48	4	and	and	CCONJ
dpc-3893	48	5	other	other	ADJ
dpc-3893	48	6	sensitive	sensitive	ADJ
dpc-3893	48	7	areas	area	NOUN
dpc-3893	48	8	,	,	PUNCT
dpc-3893	48	9	tacrolimus	tacrolimus	NOUN
dpc-3893	48	10	0.1	0.1	NUM
dpc-3893	48	11	%	%	NOUN
dpc-3893	48	12	(	(	PUNCT
dpc-3893	48	13	including	include	VERB
dpc-3893	48	14	in	in	ADP
dpc-3893	48	15	infants	infant	NOUN
dpc-3893	48	16	)	)	PUNCT
dpc-3893	48	17	or	or	CCONJ
dpc-3893	48	18	pimecrolimus	pimecrolimus	VERB
dpc-3893	48	19	1	1	NUM
dpc-3893	48	20	%	%	NOUN
dpc-3893	48	21	should	should	AUX
dpc-3893	48	22	be	be	AUX
dpc-3893	48	23	used	use	VERB
dpc-3893	48	24	twice	twice	DET
dpc-3893	48	25	a	a	DET
dpc-3893	48	26	day	day	NOUN
dpc-3893	48	27	.	.	PUNCT
dpc-3893	49	1	unfortunately	unfortunately	ADV
dpc-3893	49	2	,	,	PUNCT
dpc-3893	49	3	this	this	DET
dpc-3893	49	4	prescription	prescription	NOUN
dpc-3893	49	5	is	be	AUX
dpc-3893	49	6	still	still	ADV
dpc-3893	49	7	off	off	ADP
dpc-3893	49	8	-	-	PUNCT
dpc-3893	49	9	label	label	NOUN
dpc-3893	49	10	despite	despite	SCONJ
dpc-3893	49	11	numerous	numerous	ADJ
dpc-3893	49	12	very	very	ADV
dpc-3893	49	13	robust	robust	ADJ
dpc-3893	49	14	methodological	methodological	ADJ
dpc-3893	49	15	studies	study	NOUN
dpc-3893	49	16	[	[	X
dpc-3893	49	17	10,11	10,11	NOUN
dpc-3893	49	18	]	]	PUNCT
dpc-3893	49	19	.	.	PUNCT
dpc-3893	50	1	on	on	ADP
dpc-3893	50	2	the	the	DET
dpc-3893	50	3	body	body	NOUN
dpc-3893	50	4	,	,	PUNCT
dpc-3893	50	5	a	a	DET
dpc-3893	50	6	strong	strong	ADJ
dpc-3893	50	7	topical	topical	ADJ
dpc-3893	50	8	steroid	steroid	NOUN
dpc-3893	50	9	can	can	AUX
dpc-3893	50	10	be	be	AUX
dpc-3893	50	11	used	use	VERB
dpc-3893	50	12	instead	instead	ADV
dpc-3893	50	13	of	of	ADP
dpc-3893	50	14	tacrolimus	tacrolimus	NOUN
dpc-3893	50	15	,	,	PUNCT
dpc-3893	50	16	once	once	ADV
dpc-3893	50	17	a	a	DET
dpc-3893	50	18	day	day	NOUN
dpc-3893	50	19	,	,	PUNCT
dpc-3893	50	20	preferably	preferably	ADV
dpc-3893	50	21	in	in	ADP
dpc-3893	50	22	the	the	DET
dpc-3893	50	23	evening	evening	NOUN
dpc-3893	50	24	,	,	PUNCT
dpc-3893	50	25	and	and	CCONJ
dpc-3893	50	26	sequentially	sequentially	ADV
dpc-3893	50	27	(	(	PUNCT
dpc-3893	50	28	e.g.	e.g.	ADV
dpc-3893	50	29	5	5	NUM
dpc-3893	50	30	days	day	NOUN
dpc-3893	50	31	a	a	DET
dpc-3893	50	32	week	week	NOUN
dpc-3893	50	33	)	)	PUNCT
dpc-3893	51	1	[	[	X
dpc-3893	51	2	12	12	NUM
dpc-3893	51	3	]	]	PUNCT
dpc-3893	51	4	.	.	PUNCT
dpc-3893	52	1	the	the	DET
dpc-3893	52	2	topical	topical	ADJ
dpc-3893	52	3	jak	jak	PROPN
dpc-3893	52	4	-	-	PUNCT
dpc-3893	52	5	inhibitor	inhibitor	NOUN
dpc-3893	52	6	ruxolitinib	ruxolitinib	NOUN
dpc-3893	52	7	is	be	AUX
dpc-3893	52	8	the	the	DET
dpc-3893	52	9	first	first	ADJ
dpc-3893	52	10	treatment	treatment	NOUN
dpc-3893	52	11	approved	approve	VERB
dpc-3893	52	12	for	for	ADP
dpc-3893	52	13	vitiligo	vitiligo	NOUN
dpc-3893	52	14	both	both	PRON
dpc-3893	52	15	in	in	ADP
dpc-3893	52	16	us	we	PRON
dpc-3893	52	17	and	and	CCONJ
dpc-3893	52	18	europe	europe	PROPN
dpc-3893	52	19	for	for	ADP
dpc-3893	52	20	the	the	DET
dpc-3893	52	21	management	management	NOUN
dpc-3893	52	22	of	of	ADP
dpc-3893	52	23	vitiligo	vitiligo	NOUN
dpc-3893	52	24	affecting	affect	VERB
dpc-3893	52	25	the	the	DET
dpc-3893	52	26	face	face	NOUN
dpc-3893	52	27	and	and	CCONJ
dpc-3893	52	28	less	less	ADJ
dpc-3893	52	29	than	than	ADP
dpc-3893	52	30	10	10	NUM
dpc-3893	52	31	%	%	NOUN
dpc-3893	52	32	of	of	ADP
dpc-3893	52	33	the	the	DET
dpc-3893	52	34	body	body	NOUN
dpc-3893	52	35	surface	surface	NOUN
dpc-3893	52	36	area	area	NOUN
dpc-3893	52	37	for	for	ADP
dpc-3893	52	38	adults	adult	NOUN
dpc-3893	52	39	and	and	CCONJ
dpc-3893	52	40	adolescents	adolescent	NOUN
dpc-3893	52	41	(	(	PUNCT
dpc-3893	52	42	≥12	≥12	ADP
dpc-3893	52	43	years	year	NOUN
dpc-3893	52	44	old	old	ADJ
dpc-3893	52	45	)	)	PUNCT
dpc-3893	52	46	.	.	PUNCT
dpc-3893	53	1	two	two	NUM
dpc-3893	53	2	randomized	randomize	VERB
dpc-3893	53	3	,	,	PUNCT
dpc-3893	53	4	double	double	ADV
dpc-3893	53	5	blind	blind	ADJ
dpc-3893	53	6	,	,	PUNCT
dpc-3893	53	7	phase	phase	NOUN
dpc-3893	53	8	iii	iii	NUM
dpc-3893	53	9	studies	study	NOUN
dpc-3893	53	10	were	be	AUX
dpc-3893	53	11	conducted	conduct	VERB
dpc-3893	53	12	in	in	ADP
dpc-3893	53	13	674	674	NUM
dpc-3893	53	14	patients	patient	NOUN
dpc-3893	53	15	.	.	PUNCT
dpc-3893	54	1	patients	patient	NOUN
dpc-3893	54	2	applied	apply	VERB
dpc-3893	54	3	ruxolitinib	ruxolitinib	NOUN
dpc-3893	54	4	cream	cream	VERB
dpc-3893	54	5	1.5	1.5	NUM
dpc-3893	54	6	%	%	NOUN
dpc-3893	54	7	twice	twice	DET
dpc-3893	54	8	a	a	DET
dpc-3893	54	9	day	day	NOUN
dpc-3893	54	10	.	.	PUNCT
dpc-3893	55	1	response	response	NOUN
dpc-3893	55	2	rates	rate	NOUN
dpc-3893	55	3	were	be	AUX
dpc-3893	55	4	much	much	ADV
dpc-3893	55	5	better	well	ADJ
dpc-3893	55	6	than	than	ADP
dpc-3893	55	7	in	in	ADP
dpc-3893	55	8	the	the	DET
dpc-3893	55	9	placebo	placebo	NOUN
dpc-3893	55	10	group	group	NOUN
dpc-3893	55	11	,	,	PUNCT
dpc-3893	55	12	with	with	ADP
dpc-3893	55	13	50.3	50.3	NUM
dpc-3893	55	14	%	%	NOUN
dpc-3893	55	15	and	and	CCONJ
dpc-3893	55	16	74.6	74.6	NUM
dpc-3893	55	17	%	%	NOUN
dpc-3893	55	18	of	of	ADP
dpc-3893	55	19	patients	patient	NOUN
dpc-3893	55	20	achieving	achieve	VERB
dpc-3893	55	21	a	a	DET
dpc-3893	55	22	facial	facial	ADJ
dpc-3893	55	23	-	-	PUNCT
dpc-3893	55	24	vasi	vasi	NOUN
dpc-3893	55	25	(	(	PUNCT
dpc-3893	55	26	f	f	PROPN
dpc-3893	55	27	-	-	PUNCT
dpc-3893	55	28	vasi	vasi	NOUN
dpc-3893	55	29	)	)	PUNCT
dpc-3893	55	30	75	75	NUM
dpc-3893	55	31	and	and	CCONJ
dpc-3893	55	32	50	50	NUM
dpc-3893	55	33	,	,	PUNCT
dpc-3893	55	34	respectively	respectively	ADV
dpc-3893	55	35	,	,	PUNCT
dpc-3893	55	36	at	at	ADP
dpc-3893	55	37	week	week	NOUN
dpc-3893	55	38	52	52	NUM
dpc-3893	55	39	.	.	PUNCT
dpc-3893	56	1	moreover	moreover	ADV
dpc-3893	56	2	,	,	PUNCT
dpc-3893	56	3	51.1	51.1	NUM
dpc-3893	56	4	%	%	NOUN
dpc-3893	56	5	of	of	ADP
dpc-3893	56	6	patients	patient	NOUN
dpc-3893	56	7	achieved	achieve	VERB
dpc-3893	56	8	a	a	DET
dpc-3893	56	9	total	total	ADJ
dpc-3893	56	10	vasi	vasi	NOUN
dpc-3893	56	11	(	(	PUNCT
dpc-3893	56	12	t	t	PROPN
dpc-3893	56	13	-	-	PUNCT
dpc-3893	56	14	vasi	vasi	NOUN
dpc-3893	56	15	)	)	PUNCT
dpc-3893	56	16	of	of	ADP
dpc-3893	56	17	50	50	NUM
dpc-3893	56	18	at	at	ADP
dpc-3893	56	19	week	week	NOUN
dpc-3893	56	20	52	52	NUM
dpc-3893	57	1	[	[	X
dpc-3893	57	2	13	13	NUM
dpc-3893	57	3	]	]	PUNCT
dpc-3893	57	4	.	.	PUNCT
dpc-3893	58	1	head	head	NOUN
dpc-3893	58	2	and	and	CCONJ
dpc-3893	58	3	neck	neck	NOUN
dpc-3893	58	4	responded	respond	VERB
dpc-3893	58	5	the	the	DET
dpc-3893	58	6	best	good	ADJ
dpc-3893	58	7	,	,	PUNCT
dpc-3893	58	8	followed	follow	VERB
dpc-3893	58	9	by	by	ADP
dpc-3893	58	10	upper	upper	ADJ
dpc-3893	58	11	and	and	CCONJ
dpc-3893	58	12	lower	low	ADJ
dpc-3893	58	13	limbs	limb	NOUN
dpc-3893	58	14	,	,	PUNCT
dpc-3893	58	15	and	and	CCONJ
dpc-3893	58	16	by	by	ADP
dpc-3893	58	17	trunk	trunk	NOUN
dpc-3893	58	18	.	.	PUNCT
dpc-3893	59	1	hands	hand	NOUN
dpc-3893	59	2	and	and	CCONJ
dpc-3893	59	3	feet	foot	NOUN
dpc-3893	59	4	remained	remain	VERB
dpc-3893	59	5	the	the	DET
dpc-3893	59	6	most	most	ADV
dpc-3893	59	7	difficult	difficult	ADJ
dpc-3893	59	8	areas	area	NOUN
dpc-3893	59	9	to	to	PART
dpc-3893	59	10	repigment	repigment	VERB
dpc-3893	59	11	.	.	PUNCT
dpc-3893	60	1	interestingly	interestingly	ADV
dpc-3893	60	2	,	,	PUNCT
dpc-3893	60	3	all	all	DET
dpc-3893	60	4	the	the	DET
dpc-3893	60	5	areas	area	NOUN
dpc-3893	60	6	,	,	PUNCT
dpc-3893	60	7	excepted	except	VERB
dpc-3893	60	8	for	for	ADP
dpc-3893	60	9	hands	hand	NOUN
dpc-3893	60	10	and	and	CCONJ
dpc-3893	60	11	feet	foot	NOUN
dpc-3893	60	12	,	,	PUNCT
dpc-3893	60	13	did	do	AUX
dpc-3893	60	14	not	not	PART
dpc-3893	60	15	reach	reach	VERB
dpc-3893	60	16	a	a	DET
dpc-3893	60	17	plateau	plateau	NOUN
dpc-3893	60	18	,	,	PUNCT
dpc-3893	60	19	suggesting	suggest	VERB
dpc-3893	60	20	that	that	SCONJ
dpc-3893	60	21	longer	long	ADJ
dpc-3893	60	22	treatment	treatment	NOUN
dpc-3893	60	23	will	will	AUX
dpc-3893	60	24	allow	allow	VERB
dpc-3893	60	25	further	further	ADJ
dpc-3893	60	26	improvement	improvement	NOUN
dpc-3893	60	27	that	that	PRON
dpc-3893	60	28	was	be	AUX
dpc-3893	60	29	confirmed	confirm	VERB
dpc-3893	60	30	in	in	ADP
dpc-3893	60	31	long	long	ADJ
dpc-3893	60	32	-	-	PUNCT
dpc-3893	60	33	term	term	NOUN
dpc-3893	60	34	extension	extension	NOUN
dpc-3893	60	35	studies	study	NOUN
dpc-3893	60	36	.	.	PUNCT
dpc-3893	61	1	adverse	adverse	ADJ
dpc-3893	61	2	events	event	NOUN
dpc-3893	61	3	were	be	AUX
dpc-3893	61	4	mainly	mainly	ADV
dpc-3893	61	5	mild	mild	ADJ
dpc-3893	61	6	or	or	CCONJ
dpc-3893	61	7	moderate	moderate	ADJ
dpc-3893	61	8	.	.	PUNCT
dpc-3893	62	1	the	the	DET
dpc-3893	62	2	most	most	ADV
dpc-3893	62	3	common	common	ADJ
dpc-3893	62	4	adverse	adverse	ADJ
dpc-3893	62	5	events	event	NOUN
dpc-3893	62	6	were	be	AUX
dpc-3893	62	7	acneiform	acneiform	ADJ
dpc-3893	62	8	reactions	reaction	NOUN
dpc-3893	62	9	located	locate	VERB
dpc-3893	62	10	on	on	ADP
dpc-3893	62	11	site	site	NOUN
dpc-3893	62	12	of	of	ADP
dpc-3893	62	13	the	the	DET
dpc-3893	62	14	application	application	NOUN
dpc-3893	62	15	as	as	ADV
dpc-3893	62	16	well	well	ADV
dpc-3893	62	17	as	as	ADP
dpc-3893	62	18	pruritus	pruritus	PROPN
dpc-3893	62	19	.	.	PUNCT
dpc-3893	63	1	clinical	clinical	ADJ
dpc-3893	63	2	trials	trial	NOUN
dpc-3893	63	3	are	be	AUX
dpc-3893	63	4	ongoing	ongoing	ADJ
dpc-3893	63	5	to	to	PART
dpc-3893	63	6	see	see	VERB
dpc-3893	63	7	whether	whether	SCONJ
dpc-3893	63	8	the	the	DET
dpc-3893	63	9	efficacy	efficacy	NOUN
dpc-3893	63	10	could	could	AUX
dpc-3893	63	11	be	be	AUX
dpc-3893	63	12	better	well	ADJ
dpc-3893	63	13	in	in	ADP
dpc-3893	63	14	combination	combination	NOUN
dpc-3893	63	15	with	with	ADP
dpc-3893	63	16	uv	uv	NOUN
dpc-3893	63	17	lights	light	NOUN
dpc-3893	63	18	(	(	PUNCT
dpc-3893	63	19	nct05247489	nct05247489	NOUN
dpc-3893	63	20	)	)	PUNCT
dpc-3893	63	21	.	.	PUNCT
dpc-3893	64	1	indeed	indeed	ADV
dpc-3893	64	2	,	,	PUNCT
dpc-3893	64	3	currently	currently	ADV
dpc-3893	64	4	,	,	PUNCT
dpc-3893	64	5	without	without	ADP
dpc-3893	64	6	uv	uv	INTJ
dpc-3893	64	7	(	(	PUNCT
dpc-3893	64	8	whether	whether	SCONJ
dpc-3893	64	9	natural	natural	ADJ
dpc-3893	64	10	,	,	PUNCT
dpc-3893	64	11	cabin	cabin	NOUN
dpc-3893	64	12	,	,	PUNCT
dpc-3893	64	13	lamp	lamp	NOUN
dpc-3893	64	14	or	or	CCONJ
dpc-3893	64	15	laser	laser	NOUN
dpc-3893	64	16	)	)	PUNCT
dpc-3893	64	17	,	,	PUNCT
dpc-3893	64	18	the	the	DET
dpc-3893	64	19	repigmentation	repigmentation	NOUN
dpc-3893	64	20	is	be	AUX
dpc-3893	64	21	long	long	ADJ
dpc-3893	64	22	to	to	PART
dpc-3893	64	23	obtain	obtain	VERB
dpc-3893	64	24	.	.	PUNCT
dpc-3893	65	1	if	if	SCONJ
dpc-3893	65	2	possible	possible	ADJ
dpc-3893	65	3	,	,	PUNCT
dpc-3893	65	4	uvb	uvb	ADJ
dpc-3893	65	5	should	should	AUX
dpc-3893	65	6	be	be	AUX
dpc-3893	65	7	preferred	prefer	VERB
dpc-3893	65	8	to	to	ADP
dpc-3893	65	9	puva	puva	PROPN
dpc-3893	65	10	therapy	therapy	NOUN
dpc-3893	65	11	.	.	PUNCT
dpc-3893	66	1	for	for	ADP
dpc-3893	66	2	localized	localized	ADJ
dpc-3893	66	3	vitiligo	vitiligo	NOUN
dpc-3893	66	4	,	,	PUNCT
dpc-3893	66	5	excimer	excimer	NOUN
dpc-3893	66	6	lamps	lamp	NOUN
dpc-3893	66	7	and	and	CCONJ
dpc-3893	66	8	lasers	laser	NOUN
dpc-3893	66	9	are	be	AUX
dpc-3893	66	10	of	of	ADP
dpc-3893	66	11	great	great	ADJ
dpc-3893	66	12	interest	interest	NOUN
dpc-3893	67	1	[	[	X
dpc-3893	67	2	14–17	14–17	NUM
dpc-3893	67	3	]	]	PUNCT
dpc-3893	67	4	.	.	PUNCT
dpc-3893	68	1	it	it	PRON
dpc-3893	68	2	is	be	AUX
dpc-3893	68	3	important	important	ADJ
dpc-3893	68	4	to	to	PART
dpc-3893	68	5	note	note	VERB
dpc-3893	68	6	that	that	SCONJ
dpc-3893	68	7	there	there	PRON
dpc-3893	68	8	are	be	VERB
dpc-3893	68	9	now	now	ADV
dpc-3893	68	10	narrow	narrow	ADJ
dpc-3893	68	11	spectrum	spectrum	NOUN
dpc-3893	68	12	uvb	uvb	ADJ
dpc-3893	68	13	lamps	lamp	NOUN
dpc-3893	68	14	available	available	ADJ
dpc-3893	68	15	that	that	PRON
dpc-3893	68	16	are	be	AUX
dpc-3893	68	17	finally	finally	ADV
dpc-3893	68	18	affordable	affordable	ADJ
dpc-3893	68	19	for	for	ADP
dpc-3893	68	20	patients	patient	NOUN
dpc-3893	68	21	[	[	X
dpc-3893	68	22	18,19	18,19	X
dpc-3893	68	23	]	]	PUNCT
dpc-3893	68	24	.	.	PUNCT
dpc-3893	69	1	these	these	DET
dpc-3893	69	2	lamps	lamp	NOUN
dpc-3893	69	3	allow	allow	VERB
dpc-3893	69	4	home	home	NOUN
dpc-3893	69	5	phototherapy	phototherapy	NOUN
dpc-3893	69	6	and	and	CCONJ
dpc-3893	69	7	are	be	AUX
dpc-3893	69	8	very	very	ADV
dpc-3893	69	9	useful	useful	ADJ
dpc-3893	69	10	for	for	ADP
dpc-3893	69	11	localized	localized	ADJ
dpc-3893	69	12	lesions	lesion	NOUN
dpc-3893	69	13	of	of	ADP
dpc-3893	69	14	vitiligo	vitiligo	NOUN
dpc-3893	69	15	.	.	PUNCT
dpc-3893	70	1	sun	sun	NOUN
dpc-3893	70	2	exposure	exposure	NOUN
dpc-3893	70	3	can	can	AUX
dpc-3893	70	4	be	be	AUX
dpc-3893	70	5	offered	offer	VERB
dpc-3893	70	6	during	during	ADP
dpc-3893	70	7	the	the	DET
dpc-3893	70	8	summer	summer	NOUN
dpc-3893	70	9	season	season	NOUN
dpc-3893	70	10	.	.	PUNCT
dpc-3893	71	1	patients	patient	NOUN
dpc-3893	71	2	should	should	AUX
dpc-3893	71	3	be	be	AUX
dpc-3893	71	4	advised	advise	VERB
dpc-3893	71	5	to	to	PART
dpc-3893	71	6	expose	expose	VERB
dpc-3893	71	7	moderately	moderately	ADV
dpc-3893	71	8	themselves	themselves	PRON
dpc-3893	71	9	at	at	ADP
dpc-3893	71	10	least	least	ADV
dpc-3893	71	11	3	3	NUM
dpc-3893	71	12	or	or	CCONJ
dpc-3893	71	13	4	4	NUM
dpc-3893	71	14	times	time	NOUN
dpc-3893	71	15	a	a	DET
dpc-3893	71	16	week	week	NOUN
dpc-3893	71	17	,	,	PUNCT
dpc-3893	71	18	without	without	ADP
dpc-3893	71	19	sunscreen	sunscreen	NOUN
dpc-3893	71	20	,	,	PUNCT
dpc-3893	71	21	until	until	SCONJ
dpc-3893	71	22	their	their	PRON
dpc-3893	71	23	skin	skin	NOUN
dpc-3893	71	24	turns	turn	VERB
dpc-3893	71	25	pink	pink	ADJ
dpc-3893	71	26	.	.	PUNCT
dpc-3893	72	1	a	a	DET
dpc-3893	72	2	combination	combination	NOUN
dpc-3893	72	3	of	of	ADP
dpc-3893	72	4	sun	sun	NOUN
dpc-3893	72	5	exposure	exposure	NOUN
dpc-3893	72	6	with	with	ADP
dpc-3893	72	7	immunomodulating	immunomodulating	ADJ
dpc-3893	72	8	agents	agent	NOUN
dpc-3893	72	9	is	be	AUX
dpc-3893	72	10	crucial	crucial	ADJ
dpc-3893	72	11	to	to	PART
dpc-3893	72	12	achieve	achieve	VERB
dpc-3893	72	13	good	good	ADJ
dpc-3893	72	14	repigmentation	repigmentation	NOUN
dpc-3893	72	15	.	.	PUNCT
dpc-3893	73	1	there	there	PRON
dpc-3893	73	2	are	be	VERB
dpc-3893	73	3	now	now	ADV
dpc-3893	73	4	well	well	ADV
dpc-3893	73	5	-	-	PUNCT
dpc-3893	73	6	established	establish	VERB
dpc-3893	73	7	recommendations	recommendation	NOUN
dpc-3893	73	8	for	for	ADP
dpc-3893	73	9	using	use	VERB
dpc-3893	73	10	phototherapy	phototherapy	NOUN
dpc-3893	73	11	in	in	ADP
dpc-3893	73	12	patients	patient	NOUN
dpc-3893	73	13	with	with	ADP
dpc-3893	73	14	vitiligo	vitiligo	PROPN
dpc-3893	73	15	[	[	X
dpc-3893	73	16	17	17	NUM
dpc-3893	73	17	]	]	PUNCT
dpc-3893	73	18	.	.	PUNCT
dpc-3893	74	1	regarding	regard	VERB
dpc-3893	74	2	the	the	DET
dpc-3893	74	3	sun	sun	NOUN
dpc-3893	74	4	exposure	exposure	NOUN
dpc-3893	74	5	in	in	ADP
dpc-3893	74	6	patients	patient	NOUN
dpc-3893	74	7	with	with	ADP
dpc-3893	74	8	vitiligo	vitiligo	NOUN
dpc-3893	74	9	,	,	PUNCT
dpc-3893	74	10	it	it	PRON
dpc-3893	74	11	is	be	AUX
dpc-3893	74	12	important	important	ADJ
dpc-3893	74	13	to	to	PART
dpc-3893	74	14	note	note	VERB
dpc-3893	74	15	that	that	SCONJ
dpc-3893	74	16	patients	patient	NOUN
dpc-3893	74	17	with	with	ADP
dpc-3893	74	18	vitiligo	vitiligo	PROPN
dpc-3893	74	19	have	have	VERB
dpc-3893	74	20	a	a	DET
dpc-3893	74	21	lower	low	ADJ
dpc-3893	74	22	risk	risk	NOUN
dpc-3893	74	23	of	of	ADP
dpc-3893	74	24	developing	develop	VERB
dpc-3893	74	25	skin	skin	NOUN
dpc-3893	74	26	cancer	cancer	NOUN
dpc-3893	74	27	and	and	CCONJ
dpc-3893	74	28	in	in	ADP
dpc-3893	74	29	particular	particular	ADJ
dpc-3893	74	30	a	a	DET
dpc-3893	74	31	lower	low	ADJ
dpc-3893	74	32	risk	risk	NOUN
dpc-3893	74	33	of	of	ADP
dpc-3893	74	34	developing	develop	VERB
dpc-3893	74	35	melanoma	melanoma	NOUN
dpc-3893	74	36	.	.	PUNCT
dpc-3893	75	1	there	there	PRON
dpc-3893	75	2	is	be	VERB
dpc-3893	75	3	also	also	ADV
dpc-3893	75	4	no	no	DET
dpc-3893	75	5	increased	increased	ADJ
dpc-3893	75	6	risk	risk	NOUN
dpc-3893	75	7	of	of	ADP
dpc-3893	75	8	skin	skin	NOUN
dpc-3893	75	9	cancer	cancer	NOUN
dpc-3893	75	10	with	with	ADP
dpc-3893	75	11	narrow	narrow	ADJ
dpc-3893	75	12	-	-	PUNCT
dpc-3893	75	13	spectrum	spectrum	NOUN
dpc-3893	75	14	review	review	NOUN
dpc-3893	75	15	|	|	ADV
dpc-3893	75	16	dermatol	dermatol	ADJ
dpc-3893	75	17	pract	pract	NOUN
dpc-3893	75	18	concept	concept	NOUN
dpc-3893	75	19	.	.	PUNCT
dpc-3893	76	1	2023;13(4)s2	2023;13(4)s2	NOUN
dpc-3893	76	2	:	:	PUNCT
dpc-3893	76	3	e2023313s	e2023313s	PROPN
dpc-3893	76	4	3	3	NUM
dpc-3893	76	5	uvb	uvb	ADJ
dpc-3893	76	6	phototherapy	phototherapy	NOUN
dpc-3893	76	7	in	in	ADP
dpc-3893	76	8	vitiligo	vitiligo	NOUN
dpc-3893	76	9	(	(	PUNCT
dpc-3893	76	10	up	up	ADP
dpc-3893	76	11	to	to	PART
dpc-3893	76	12	at	at	ADV
dpc-3893	76	13	least	least	ADV
dpc-3893	76	14	400	400	NUM
dpc-3893	76	15	sessions	session	NOUN
dpc-3893	76	16	)	)	PUNCT
dpc-3893	76	17	.	.	PUNCT
dpc-3893	77	1	in	in	ADP
dpc-3893	77	2	addition	addition	NOUN
dpc-3893	77	3	,	,	PUNCT
dpc-3893	77	4	no	no	DET
dpc-3893	77	5	increased	increased	ADJ
dpc-3893	77	6	risk	risk	NOUN
dpc-3893	77	7	of	of	ADP
dpc-3893	77	8	skin	skin	NOUN
dpc-3893	77	9	cancers	cancer	NOUN
dpc-3893	77	10	has	have	AUX
dpc-3893	77	11	been	be	AUX
dpc-3893	77	12	shown	show	VERB
dpc-3893	77	13	if	if	SCONJ
dpc-3893	77	14	nb	nb	NOUN
dpc-3893	77	15	-	-	ADJ
dpc-3893	77	16	uvb	uvb	NOUN
dpc-3893	77	17	is	be	AUX
dpc-3893	77	18	combined	combine	VERB
dpc-3893	77	19	with	with	ADP
dpc-3893	77	20	tacrolimus	tacrolimus	NOUN
dpc-3893	77	21	[	[	X
dpc-3893	77	22	20–22	20–22	NUM
dpc-3893	77	23	]	]	PUNCT
dpc-3893	77	24	.	.	PUNCT
dpc-3893	78	1	what	what	PRON
dpc-3893	78	2	is	be	AUX
dpc-3893	78	3	the	the	DET
dpc-3893	78	4	place	place	NOUN
dpc-3893	78	5	of	of	ADP
dpc-3893	78	6	melanocyte	melanocyte	NOUN
dpc-3893	78	7	-	-	PUNCT
dpc-3893	78	8	grafting	grafting	NOUN
dpc-3893	78	9	?	?	PUNCT
dpc-3893	79	1	transplants	transplant	NOUN
dpc-3893	79	2	have	have	VERB
dpc-3893	79	3	two	two	NUM
dpc-3893	79	4	main	main	ADJ
dpc-3893	79	5	indications	indication	NOUN
dpc-3893	79	6	in	in	ADP
dpc-3893	79	7	vitiligo	vitiligo	NOUN
dpc-3893	79	8	.	.	PUNCT
dpc-3893	80	1	they	they	PRON
dpc-3893	80	2	can	can	AUX
dpc-3893	80	3	be	be	AUX
dpc-3893	80	4	proposed	propose	VERB
dpc-3893	80	5	after	after	ADP
dpc-3893	80	6	the	the	DET
dpc-3893	80	7	failure	failure	NOUN
dpc-3893	80	8	of	of	ADP
dpc-3893	80	9	medical	medical	ADJ
dpc-3893	80	10	treatments	treatment	NOUN
dpc-3893	80	11	for	for	ADP
dpc-3893	80	12	:	:	PUNCT
dpc-3893	80	13	vitiligo	vitiligo	NOUN
dpc-3893	80	14	that	that	PRON
dpc-3893	80	15	has	have	AUX
dpc-3893	80	16	been	be	AUX
dpc-3893	80	17	stable	stable	ADJ
dpc-3893	80	18	for	for	ADP
dpc-3893	80	19	at	at	ADV
dpc-3893	80	20	least	least	ADV
dpc-3893	80	21	12	12	NUM
dpc-3893	80	22	months	month	NOUN
dpc-3893	80	23	and	and	CCONJ
dpc-3893	80	24	segmental	segmental	ADJ
dpc-3893	80	25	vitiligo	vitiligo	NOUN
dpc-3893	80	26	.	.	PUNCT
dpc-3893	81	1	several	several	ADJ
dpc-3893	81	2	techniques	technique	NOUN
dpc-3893	81	3	have	have	AUX
dpc-3893	81	4	been	be	AUX
dpc-3893	81	5	described	describe	VERB
dpc-3893	81	6	:	:	PUNCT
dpc-3893	81	7	–	–	PUNCT
dpc-3893	81	8	epidermal	epidermal	ADJ
dpc-3893	81	9	suspensions	suspension	NOUN
dpc-3893	81	10	;	;	PUNCT
dpc-3893	81	11	–	–	PUNCT
dpc-3893	81	12	epidermal	epidermal	ADJ
dpc-3893	81	13	suction	suction	NOUN
dpc-3893	81	14	and	and	CCONJ
dpc-3893	81	15	then	then	ADV
dpc-3893	81	16	grafting	graft	VERB
dpc-3893	81	17	;	;	PUNCT
dpc-3893	81	18	–	–	PUNCT
dpc-3893	81	19	thin	thin	ADJ
dpc-3893	81	20	skin	skin	NOUN
dpc-3893	81	21	grafting	grafting	NOUN
dpc-3893	81	22	;	;	PUNCT
dpc-3893	81	23	–	–	PUNCT
dpc-3893	81	24	mini	mini	NOUN
dpc-3893	81	25	-	-	NOUN
dpc-3893	81	26	grafting	grafting	NOUN
dpc-3893	81	27	;	;	PUNCT
dpc-3893	81	28	–	–	PUNCT
dpc-3893	81	29	in	in	X
dpc-3893	81	30	vitro	vitro	X
dpc-3893	81	31	culture	culture	NOUN
dpc-3893	81	32	of	of	ADP
dpc-3893	81	33	keratinocyte	keratinocyte	NOUN
dpc-3893	81	34	and	and	CCONJ
dpc-3893	81	35	melanocyte	melanocyte	NOUN
dpc-3893	81	36	suspensions	suspension	NOUN
dpc-3893	81	37	.	.	PUNCT
dpc-3893	82	1	epidermal	epidermal	ADJ
dpc-3893	82	2	suspensions	suspension	NOUN
dpc-3893	82	3	are	be	AUX
dpc-3893	82	4	preferred	prefer	VERB
dpc-3893	82	5	and	and	CCONJ
dpc-3893	82	6	now	now	ADV
dpc-3893	82	7	approved	approve	VERB
dpc-3893	82	8	commercial	commercial	ADJ
dpc-3893	82	9	tissue	tissue	NOUN
dpc-3893	82	10	-	-	PUNCT
dpc-3893	82	11	dissociation	dissociation	NOUN
dpc-3893	82	12	kits	kit	NOUN
dpc-3893	82	13	can	can	AUX
dpc-3893	82	14	be	be	AUX
dpc-3893	82	15	used	use	VERB
dpc-3893	82	16	in	in	ADP
dpc-3893	82	17	the	the	DET
dpc-3893	82	18	clinic	clinic	NOUN
dpc-3893	82	19	[	[	X
dpc-3893	82	20	23,24	23,24	ADP
dpc-3893	82	21	]	]	PUNCT
dpc-3893	82	22	.	.	PUNCT
dpc-3893	83	1	how	how	SCONJ
dpc-3893	83	2	can	can	AUX
dpc-3893	83	3	recurrences	recurrence	NOUN
dpc-3893	83	4	be	be	AUX
dpc-3893	83	5	prevented	prevent	VERB
dpc-3893	83	6	?	?	PUNCT
dpc-3893	84	1	almost	almost	ADV
dpc-3893	84	2	50	50	NUM
dpc-3893	84	3	%	%	NOUN
dpc-3893	84	4	of	of	ADP
dpc-3893	84	5	vitiligo	vitiligo	ADJ
dpc-3893	84	6	lesions	lesion	NOUN
dpc-3893	84	7	recur	recur	VERB
dpc-3893	84	8	in	in	ADP
dpc-3893	84	9	the	the	DET
dpc-3893	84	10	first	first	ADJ
dpc-3893	84	11	year	year	NOUN
dpc-3893	84	12	after	after	ADP
dpc-3893	84	13	repigmentation	repigmentation	NOUN
dpc-3893	84	14	without	without	ADP
dpc-3893	84	15	a	a	DET
dpc-3893	84	16	maintenance	maintenance	NOUN
dpc-3893	84	17	therapy	therapy	NOUN
dpc-3893	84	18	[	[	X
dpc-3893	84	19	25	25	NUM
dpc-3893	84	20	]	]	PUNCT
dpc-3893	84	21	.	.	PUNCT
dpc-3893	85	1	for	for	ADP
dpc-3893	85	2	instance	instance	NOUN
dpc-3893	85	3	for	for	ADP
dpc-3893	85	4	the	the	DET
dpc-3893	85	5	face	face	NOUN
dpc-3893	85	6	,	,	PUNCT
dpc-3893	85	7	it	it	PRON
dpc-3893	85	8	has	have	AUX
dpc-3893	85	9	been	be	AUX
dpc-3893	85	10	shown	show	VERB
dpc-3893	85	11	than	than	ADP
dpc-3893	85	12	the	the	DET
dpc-3893	85	13	use	use	NOUN
dpc-3893	85	14	of	of	ADP
dpc-3893	85	15	tacrolimus	tacrolimus	NOUN
dpc-3893	85	16	0.1	0.1	NUM
dpc-3893	85	17	%	%	NOUN
dpc-3893	85	18	twice	twice	ADV
dpc-3893	85	19	weekly	weekly	ADJ
dpc-3893	85	20	(	(	PUNCT
dpc-3893	85	21	without	without	ADP
dpc-3893	85	22	the	the	DET
dpc-3893	85	23	need	need	NOUN
dpc-3893	85	24	of	of	ADP
dpc-3893	85	25	sun	sun	NOUN
dpc-3893	85	26	exposure	exposure	NOUN
dpc-3893	85	27	)	)	PUNCT
dpc-3893	85	28	reduces	reduce	VERB
dpc-3893	85	29	the	the	DET
dpc-3893	85	30	risk	risk	NOUN
dpc-3893	85	31	of	of	ADP
dpc-3893	85	32	relapse	relapse	NOUN
dpc-3893	85	33	from	from	ADP
dpc-3893	85	34	40	40	NUM
dpc-3893	85	35	%	%	NOUN
dpc-3893	85	36	to	to	ADP
dpc-3893	85	37	9.7	9.7	NUM
dpc-3893	85	38	%	%	NOUN
dpc-3893	86	1	[	[	X
dpc-3893	86	2	26	26	NUM
dpc-3893	86	3	]	]	PUNCT
dpc-3893	86	4	.	.	PUNCT
dpc-3893	87	1	topical	topical	ADJ
dpc-3893	87	2	steroids	steroid	NOUN
dpc-3893	87	3	on	on	ADP
dpc-3893	87	4	the	the	DET
dpc-3893	87	5	same	same	ADJ
dpc-3893	87	6	schedule	schedule	NOUN
dpc-3893	87	7	are	be	AUX
dpc-3893	87	8	probably	probably	ADV
dpc-3893	87	9	also	also	ADV
dpc-3893	87	10	effective	effective	ADJ
dpc-3893	87	11	but	but	CCONJ
dpc-3893	87	12	this	this	PRON
dpc-3893	87	13	has	have	AUX
dpc-3893	87	14	not	not	PART
dpc-3893	87	15	been	be	AUX
dpc-3893	87	16	yet	yet	ADV
dpc-3893	87	17	demonstrated	demonstrate	VERB
dpc-3893	87	18	.	.	PUNCT
dpc-3893	88	1	for	for	ADP
dpc-3893	88	2	patients	patient	NOUN
dpc-3893	88	3	with	with	ADP
dpc-3893	88	4	a	a	DET
dpc-3893	88	5	larger	large	ADJ
dpc-3893	88	6	extent	extent	NOUN
dpc-3893	88	7	of	of	ADP
dpc-3893	88	8	the	the	DET
dpc-3893	88	9	disease	disease	NOUN
dpc-3893	88	10	,	,	PUNCT
dpc-3893	88	11	the	the	DET
dpc-3893	88	12	use	use	NOUN
dpc-3893	88	13	of	of	ADP
dpc-3893	88	14	nb	nb	NOUN
dpc-3893	88	15	-	-	PUNCT
dpc-3893	88	16	uvb	uvb	ADJ
dpc-3893	88	17	once	once	ADV
dpc-3893	88	18	or	or	CCONJ
dpc-3893	88	19	twice	twice	DET
dpc-3893	88	20	a	a	DET
dpc-3893	88	21	month	month	NOUN
dpc-3893	88	22	as	as	ADP
dpc-3893	88	23	a	a	DET
dpc-3893	88	24	maintenance	maintenance	NOUN
dpc-3893	88	25	treatment	treatment	NOUN
dpc-3893	88	26	could	could	AUX
dpc-3893	88	27	be	be	AUX
dpc-3893	88	28	discussed	discuss	VERB
dpc-3893	88	29	[	[	X
dpc-3893	88	30	17	17	NUM
dpc-3893	88	31	]	]	PUNCT
dpc-3893	88	32	.	.	PUNCT
dpc-3893	89	1	however	however	ADV
dpc-3893	89	2	,	,	PUNCT
dpc-3893	89	3	data	datum	NOUN
dpc-3893	89	4	supporting	support	VERB
dpc-3893	89	5	this	this	DET
dpc-3893	89	6	procedure	procedure	NOUN
dpc-3893	89	7	are	be	AUX
dpc-3893	89	8	still	still	ADV
dpc-3893	89	9	lacking	lack	VERB
dpc-3893	89	10	.	.	PUNCT
dpc-3893	90	1	some	some	DET
dpc-3893	90	2	systemic	systemic	ADJ
dpc-3893	90	3	treatments	treatment	NOUN
dpc-3893	90	4	currently	currently	ADV
dpc-3893	90	5	under	under	ADP
dpc-3893	90	6	development	development	NOUN
dpc-3893	90	7	may	may	AUX
dpc-3893	90	8	be	be	AUX
dpc-3893	90	9	of	of	ADP
dpc-3893	90	10	interest	interest	NOUN
dpc-3893	90	11	to	to	PART
dpc-3893	90	12	block	block	VERB
dpc-3893	90	13	the	the	DET
dpc-3893	90	14	recurrence	recurrence	NOUN
dpc-3893	90	15	of	of	ADP
dpc-3893	90	16	vitiligo	vitiligo	NOUN
dpc-3893	90	17	.	.	PUNCT
dpc-3893	91	1	when	when	SCONJ
dpc-3893	91	2	and	and	CCONJ
dpc-3893	91	3	how	how	SCONJ
dpc-3893	91	4	to	to	PART
dpc-3893	91	5	propose	propose	VERB
dpc-3893	91	6	depigmentation	depigmentation	NOUN
dpc-3893	91	7	?	?	PUNCT
dpc-3893	92	1	depigmentation	depigmentation	NOUN
dpc-3893	92	2	can	can	AUX
dpc-3893	92	3	be	be	AUX
dpc-3893	92	4	discussed	discuss	VERB
dpc-3893	92	5	for	for	ADP
dpc-3893	92	6	patients	patient	NOUN
dpc-3893	92	7	with	with	ADP
dpc-3893	92	8	depigmented	depigmented	ADJ
dpc-3893	92	9	areas	area	NOUN
dpc-3893	92	10	affecting	affect	VERB
dpc-3893	92	11	more	more	ADJ
dpc-3893	92	12	than	than	ADP
dpc-3893	92	13	50	50	NUM
dpc-3893	92	14	%	%	NOUN
dpc-3893	92	15	of	of	ADP
dpc-3893	92	16	the	the	DET
dpc-3893	92	17	body	body	NOUN
dpc-3893	92	18	.	.	PUNCT
dpc-3893	93	1	chemical	chemical	NOUN
dpc-3893	93	2	depigmenting	depigmente	VERB
dpc-3893	93	3	products	product	NOUN
dpc-3893	93	4	such	such	ADJ
dpc-3893	93	5	as	as	ADP
dpc-3893	93	6	mebh	mebh	X
dpc-3893	93	7	(	(	PUNCT
dpc-3893	93	8	hydroquinone	hydroquinone	NOUN
dpc-3893	93	9	monobenzylether	monobenzylether	NOUN
dpc-3893	93	10	)	)	PUNCT
dpc-3893	93	11	are	be	AUX
dpc-3893	93	12	no	no	ADV
dpc-3893	93	13	longer	long	ADV
dpc-3893	93	14	available	available	ADJ
dpc-3893	93	15	in	in	ADP
dpc-3893	93	16	most	most	ADJ
dpc-3893	93	17	of	of	ADP
dpc-3893	93	18	european	european	ADJ
dpc-3893	93	19	countries	country	NOUN
dpc-3893	93	20	.	.	PUNCT
dpc-3893	94	1	depigmenting	depigmente	VERB
dpc-3893	94	2	lasers	laser	NOUN
dpc-3893	94	3	have	have	AUX
dpc-3893	94	4	shown	show	VERB
dpc-3893	94	5	similar	similar	ADJ
dpc-3893	94	6	approximately	approximately	ADV
dpc-3893	94	7	a	a	DET
dpc-3893	94	8	70	70	NUM
dpc-3893	94	9	%	%	NOUN
dpc-3893	94	10	success	success	NOUN
dpc-3893	94	11	rate	rate	NOUN
dpc-3893	94	12	after	after	ADP
dpc-3893	94	13	1	1	NUM
dpc-3893	94	14	to	to	PART
dpc-3893	94	15	3	3	NUM
dpc-3893	94	16	sessions	session	NOUN
dpc-3893	94	17	.	.	PUNCT
dpc-3893	95	1	maintenance	maintenance	NOUN
dpc-3893	95	2	sessions	session	NOUN
dpc-3893	95	3	after	after	ADP
dpc-3893	95	4	the	the	DET
dpc-3893	95	5	summer	summer	NOUN
dpc-3893	95	6	are	be	AUX
dpc-3893	95	7	often	often	ADV
dpc-3893	95	8	necessary	necessary	ADJ
dpc-3893	95	9	,	,	PUNCT
dpc-3893	95	10	especially	especially	ADV
dpc-3893	95	11	on	on	ADP
dpc-3893	95	12	light	light	ADJ
dpc-3893	95	13	exposed	expose	VERB
dpc-3893	95	14	areas	area	NOUN
dpc-3893	95	15	such	such	ADJ
dpc-3893	95	16	as	as	ADP
dpc-3893	95	17	the	the	DET
dpc-3893	95	18	face	face	NOUN
dpc-3893	95	19	.	.	PUNCT
dpc-3893	96	1	for	for	ADP
dpc-3893	96	2	small	small	ADJ
dpc-3893	96	3	areas	area	NOUN
dpc-3893	96	4	,	,	PUNCT
dpc-3893	96	5	cryotherapy	cryotherapy	NOUN
dpc-3893	96	6	is	be	AUX
dpc-3893	96	7	an	an	DET
dpc-3893	96	8	interesting	interesting	ADJ
dpc-3893	96	9	option	option	NOUN
dpc-3893	96	10	[	[	X
dpc-3893	96	11	27,28	27,28	NUM
dpc-3893	96	12	]	]	X
dpc-3893	96	13	.	.	PUNCT
dpc-3893	97	1	future	future	ADJ
dpc-3893	97	2	therapies	therapy	NOUN
dpc-3893	97	3	in	in	ADP
dpc-3893	97	4	development	development	NOUN
dpc-3893	97	5	vitiligo	vitiligo	NOUN
dpc-3893	97	6	patients	patient	NOUN
dpc-3893	97	7	can	can	AUX
dpc-3893	97	8	be	be	AUX
dpc-3893	97	9	strongly	strongly	ADV
dpc-3893	97	10	encouraged	encourage	VERB
dpc-3893	97	11	to	to	PART
dpc-3893	97	12	participate	participate	VERB
dpc-3893	97	13	in	in	ADP
dpc-3893	97	14	the	the	DET
dpc-3893	97	15	latest	late	ADJ
dpc-3893	97	16	clinical	clinical	ADJ
dpc-3893	97	17	trials	trial	NOUN
dpc-3893	97	18	to	to	PART
dpc-3893	97	19	promote	promote	VERB
dpc-3893	97	20	the	the	DET
dpc-3893	97	21	development	development	NOUN
dpc-3893	97	22	of	of	ADP
dpc-3893	97	23	new	new	ADJ
dpc-3893	97	24	and	and	CCONJ
dpc-3893	97	25	more	more	ADV
dpc-3893	97	26	efficient	efficient	ADJ
dpc-3893	97	27	therapies	therapy	NOUN
dpc-3893	97	28	.	.	PUNCT
dpc-3893	98	1	besides	besides	SCONJ
dpc-3893	98	2	the	the	DET
dpc-3893	98	3	approval	approval	NOUN
dpc-3893	98	4	of	of	ADP
dpc-3893	98	5	topical	topical	ADJ
dpc-3893	98	6	ruxolitinib	ruxolitinib	NOUN
dpc-3893	98	7	both	both	PRON
dpc-3893	98	8	in	in	ADP
dpc-3893	98	9	us	we	PRON
dpc-3893	98	10	and	and	CCONJ
dpc-3893	98	11	europe	europe	PROPN
dpc-3893	98	12	,	,	PUNCT
dpc-3893	98	13	the	the	DET
dpc-3893	98	14	oral	oral	ADJ
dpc-3893	98	15	jak	jak	PROPN
dpc-3893	98	16	inhibitors	inhibitor	NOUN
dpc-3893	98	17	baracitinib	baracitinib	NOUN
dpc-3893	98	18	(	(	PUNCT
dpc-3893	98	19	a	a	DET
dpc-3893	98	20	jak1/2	jak1/2	PROPN
dpc-3893	98	21	inhibitor	inhibitor	NOUN
dpc-3893	98	22	)	)	PUNCT
dpc-3893	98	23	,	,	PUNCT
dpc-3893	98	24	upadacitinib	upadacitinib	NOUN
dpc-3893	98	25	and	and	CCONJ
dpc-3893	98	26	povorcitinib	povorcitinib	NOUN
dpc-3893	98	27	(	(	PUNCT
dpc-3893	98	28	jak1	jak1	PROPN
dpc-3893	98	29	inhibitors	inhibitor	NOUN
dpc-3893	98	30	are	be	AUX
dpc-3893	98	31	currently	currently	ADV
dpc-3893	98	32	being	be	AUX
dpc-3893	98	33	tested	test	VERB
dpc-3893	98	34	in	in	ADP
dpc-3893	98	35	phase	phase	NOUN
dpc-3893	98	36	ii	ii	NOUN
dpc-3893	98	37	ongoing	ongoing	ADJ
dpc-3893	98	38	trials	trial	NOUN
dpc-3893	98	39	.	.	PUNCT
dpc-3893	99	1	ritlecitinib	ritlecitinib	NOUN
dpc-3893	99	2	(	(	PUNCT
dpc-3893	99	3	a	a	DET
dpc-3893	99	4	jak3	jak3	NOUN
dpc-3893	99	5	/	/	SYM
dpc-3893	99	6	tec	tec	ADJ
dpc-3893	99	7	inhibitor	inhibitor	NOUN
dpc-3893	99	8	)	)	PUNCT
dpc-3893	99	9	was	be	AUX
dpc-3893	99	10	recently	recently	ADV
dpc-3893	99	11	evaluated	evaluate	VERB
dpc-3893	99	12	with	with	ADP
dpc-3893	99	13	different	different	ADJ
dpc-3893	99	14	doses	dose	NOUN
dpc-3893	99	15	in	in	ADP
dpc-3893	99	16	a	a	DET
dpc-3893	99	17	phase	phase	NOUN
dpc-3893	99	18	ii	ii	NOUN
dpc-3893	99	19	trial	trial	NOUN
dpc-3893	99	20	that	that	PRON
dpc-3893	99	21	included	include	VERB
dpc-3893	99	22	364	364	NUM
dpc-3893	99	23	patients	patient	NOUN
dpc-3893	99	24	[	[	X
dpc-3893	99	25	29	29	NUM
dpc-3893	99	26	]	]	PUNCT
dpc-3893	99	27	.	.	PUNCT
dpc-3893	100	1	after	after	ADP
dpc-3893	100	2	24	24	NUM
dpc-3893	100	3	weeks	week	NOUN
dpc-3893	100	4	,	,	PUNCT
dpc-3893	100	5	the	the	DET
dpc-3893	100	6	proportion	proportion	NOUN
dpc-3893	100	7	of	of	ADP
dpc-3893	100	8	f	f	PROPN
dpc-3893	100	9	-	-	PUNCT
dpc-3893	100	10	vasi	vasi	PROPN
dpc-3893	100	11	change	change	NOUN
dpc-3893	100	12	from	from	ADP
dpc-3893	100	13	baseline	baseline	PROPN
dpc-3893	100	14	was	be	AUX
dpc-3893	100	15	significantly	significantly	ADV
dpc-3893	100	16	different	different	ADJ
dpc-3893	100	17	in	in	ADP
dpc-3893	100	18	the	the	DET
dpc-3893	100	19	ritlecitinib	ritlecitinib	NOUN
dpc-3893	100	20	50	50	NUM
dpc-3893	100	21	mg	mg	PROPN
dpc-3893	100	22	group	group	NOUN
dpc-3893	100	23	compared	compare	VERB
dpc-3893	100	24	to	to	ADP
dpc-3893	100	25	placebo	placebo	NOUN
dpc-3893	100	26	for	for	ADP
dpc-3893	100	27	the	the	DET
dpc-3893	100	28	with	with	ADP
dpc-3893	100	29	(	(	PUNCT
dpc-3893	100	30	-21.2	-21.2	INTJ
dpc-3893	100	31	%	%	NOUN
dpc-3893	100	32	vs	vs	ADP
dpc-3893	100	33	2.1	2.1	NUM
dpc-3893	100	34	%	%	NOUN
dpc-3893	100	35	,	,	PUNCT
dpc-3893	100	36	p<0.001	p<0.001	PROPN
dpc-3893	100	37	)	)	PUNCT
dpc-3893	100	38	.	.	PUNCT
dpc-3893	101	1	strategies	strategy	NOUN
dpc-3893	101	2	to	to	PART
dpc-3893	101	3	target	target	VERB
dpc-3893	101	4	il-15	il-15	NOUN
dpc-3893	101	5	or	or	CCONJ
dpc-3893	101	6	its	its	PRON
dpc-3893	101	7	receptor	receptor	NOUN
dpc-3893	101	8	cd122	cd122	PROPN
dpc-3893	101	9	to	to	PART
dpc-3893	101	10	inhibit	inhibit	VERB
dpc-3893	101	11	the	the	DET
dpc-3893	101	12	generation	generation	NOUN
dpc-3893	101	13	and	and	CCONJ
dpc-3893	101	14	the	the	DET
dpc-3893	101	15	maintenance	maintenance	NOUN
dpc-3893	101	16	of	of	ADP
dpc-3893	101	17	skin	skin	NOUN
dpc-3893	101	18	resident	resident	NOUN
dpc-3893	101	19	memory	memory	NOUN
dpc-3893	101	20	t	t	PROPN
dpc-3893	101	21	cells	cell	NOUN
dpc-3893	101	22	demonstrated	demonstrate	VERB
dpc-3893	101	23	durable	durable	ADJ
dpc-3893	101	24	treatment	treatment	NOUN
dpc-3893	101	25	responses	response	NOUN
dpc-3893	101	26	in	in	ADP
dpc-3893	101	27	a	a	DET
dpc-3893	101	28	pre	pre	ADJ
dpc-3893	101	29	-	-	ADJ
dpc-3893	101	30	clinical	clinical	ADJ
dpc-3893	101	31	mouse	mouse	NOUN
dpc-3893	101	32	model	model	NOUN
dpc-3893	101	33	of	of	ADP
dpc-3893	101	34	vitiligo	vitiligo	PROPN
dpc-3893	101	35	and	and	CCONJ
dpc-3893	101	36	clinical	clinical	ADJ
dpc-3893	101	37	trials	trial	NOUN
dpc-3893	101	38	using	use	VERB
dpc-3893	101	39	this	this	DET
dpc-3893	101	40	strategy	strategy	NOUN
dpc-3893	101	41	are	be	AUX
dpc-3893	101	42	under	under	ADP
dpc-3893	101	43	way	way	NOUN
dpc-3893	101	44	[	[	X
dpc-3893	101	45	30	30	NUM
dpc-3893	101	46	]	]	PUNCT
dpc-3893	101	47	.	.	PUNCT
dpc-3893	102	1	blocking	block	VERB
dpc-3893	102	2	the	the	DET
dpc-3893	102	3	initiation	initiation	NOUN
dpc-3893	102	4	of	of	ADP
dpc-3893	102	5	the	the	DET
dpc-3893	102	6	disease	disease	NOUN
dpc-3893	102	7	could	could	AUX
dpc-3893	102	8	be	be	AUX
dpc-3893	102	9	also	also	ADV
dpc-3893	102	10	an	an	DET
dpc-3893	102	11	important	important	ADJ
dpc-3893	102	12	step	step	NOUN
dpc-3893	102	13	for	for	ADP
dpc-3893	102	14	future	future	ADJ
dpc-3893	102	15	therapies	therapy	NOUN
dpc-3893	102	16	in	in	ADP
dpc-3893	102	17	vitiligo	vitiligo	PROPN
dpc-3893	102	18	.	.	PUNCT
dpc-3893	103	1	hp70i	hp70i	PROPN
dpc-3893	103	2	seems	seem	VERB
dpc-3893	103	3	to	to	PART
dpc-3893	103	4	be	be	AUX
dpc-3893	103	5	a	a	DET
dpc-3893	103	6	critical	critical	ADJ
dpc-3893	103	7	danger	danger	NOUN
dpc-3893	103	8	associated	associate	VERB
dpc-3893	103	9	molecular	molecular	ADJ
dpc-3893	103	10	pattern	pattern	NOUN
dpc-3893	103	11	(	(	PUNCT
dpc-3893	103	12	damp	damp	NOUN
dpc-3893	103	13	)	)	PUNCT
dpc-3893	103	14	important	important	ADJ
dpc-3893	103	15	for	for	ADP
dpc-3893	103	16	the	the	DET
dpc-3893	103	17	initiation	initiation	NOUN
dpc-3893	103	18	of	of	ADP
dpc-3893	103	19	the	the	DET
dpc-3893	103	20	disease	disease	NOUN
dpc-3893	103	21	.	.	PUNCT
dpc-3893	104	1	blocking	block	VERB
dpc-3893	104	2	hsp70i	hsp70i	NOUN
dpc-3893	104	3	activity	activity	NOUN
dpc-3893	104	4	might	might	AUX
dpc-3893	104	5	offer	offer	VERB
dpc-3893	104	6	a	a	DET
dpc-3893	104	7	good	good	ADJ
dpc-3893	104	8	strategy	strategy	NOUN
dpc-3893	104	9	as	as	SCONJ
dpc-3893	104	10	shown	show	VERB
dpc-3893	104	11	in	in	ADP
dpc-3893	104	12	pre	pre	ADJ
dpc-3893	104	13	-	-	ADJ
dpc-3893	104	14	clinical	clinical	ADJ
dpc-3893	104	15	animal	animal	NOUN
dpc-3893	104	16	models	model	NOUN
dpc-3893	104	17	[	[	X
dpc-3893	104	18	31–33	31–33	NUM
dpc-3893	104	19	]	]	PUNCT
dpc-3893	104	20	.	.	PUNCT
dpc-3893	105	1	preventing	prevent	VERB
dpc-3893	105	2	melanocyte	melanocyte	NOUN
dpc-3893	105	3	detachment	detachment	NOUN
dpc-3893	105	4	by	by	ADP
dpc-3893	105	5	using	use	VERB
dpc-3893	105	6	matrix	matrix	NOUN
dpc-3893	105	7	metalloproteinase-9	metalloproteinase-9	NUM
dpc-3893	105	8	inhibitors	inhibitor	NOUN
dpc-3893	105	9	could	could	AUX
dpc-3893	105	10	also	also	ADV
dpc-3893	105	11	be	be	AUX
dpc-3893	105	12	effective	effective	ADJ
dpc-3893	105	13	[	[	X
dpc-3893	105	14	34	34	NUM
dpc-3893	105	15	]	]	PUNCT
dpc-3893	105	16	.	.	PUNCT
dpc-3893	106	1	recent	recent	ADJ
dpc-3893	106	2	data	datum	NOUN
dpc-3893	106	3	suggest	suggest	VERB
dpc-3893	106	4	a	a	DET
dpc-3893	106	5	dysbiosis	dysbiosis	NOUN
dpc-3893	106	6	in	in	ADP
dpc-3893	106	7	the	the	DET
dpc-3893	106	8	skin	skin	NOUN
dpc-3893	106	9	and	and	CCONJ
dpc-3893	106	10	the	the	DET
dpc-3893	106	11	gut	gut	NOUN
dpc-3893	106	12	of	of	ADP
dpc-3893	106	13	vitiligo	vitiligo	ADJ
dpc-3893	106	14	patients	patient	NOUN
dpc-3893	106	15	.	.	PUNCT
dpc-3893	107	1	modulating	modulate	VERB
dpc-3893	107	2	the	the	DET
dpc-3893	107	3	vitiligo	vitiligo	NOUN
dpc-3893	107	4	microbiome	microbiome	NOUN
dpc-3893	107	5	offers	offer	VERB
dpc-3893	107	6	potential	potential	ADJ
dpc-3893	107	7	new	new	ADJ
dpc-3893	107	8	strategies	strategy	NOUN
dpc-3893	107	9	[	[	X
dpc-3893	107	10	35	35	NUM
dpc-3893	107	11	]	]	PUNCT
dpc-3893	107	12	.	.	PUNCT
dpc-3893	108	1	in	in	ADP
dpc-3893	108	2	addition	addition	NOUN
dpc-3893	108	3	,	,	PUNCT
dpc-3893	108	4	to	to	PART
dpc-3893	108	5	induce	induce	VERB
dpc-3893	108	6	a	a	DET
dpc-3893	108	7	better	well	ADJ
dpc-3893	108	8	repigmentation	repigmentation	NOUN
dpc-3893	108	9	,	,	PUNCT
dpc-3893	108	10	it	it	PRON
dpc-3893	108	11	will	will	AUX
dpc-3893	108	12	be	be	AUX
dpc-3893	108	13	important	important	ADJ
dpc-3893	108	14	to	to	PART
dpc-3893	108	15	combine	combine	VERB
dpc-3893	108	16	topical	topical	ADJ
dpc-3893	108	17	and/or	and/or	CCONJ
dpc-3893	108	18	oral	oral	ADJ
dpc-3893	108	19	immunomodulators	immunomodulator	NOUN
dpc-3893	108	20	with	with	ADP
dpc-3893	108	21	strategies	strategy	NOUN
dpc-3893	108	22	that	that	PRON
dpc-3893	108	23	will	will	AUX
dpc-3893	108	24	promote	promote	VERB
dpc-3893	108	25	the	the	DET
dpc-3893	108	26	differentiation	differentiation	NOUN
dpc-3893	108	27	and	and	CCONJ
dpc-3893	108	28	proliferation	proliferation	NOUN
dpc-3893	108	29	of	of	ADP
dpc-3893	108	30	melanocyte	melanocyte	NOUN
dpc-3893	108	31	stem	stem	NOUN
dpc-3893	108	32	cells	cell	NOUN
dpc-3893	108	33	in	in	ADP
dpc-3893	108	34	vitiligo	vitiligo	NOUN
dpc-3893	108	35	lesions	lesion	NOUN
dpc-3893	108	36	,	,	PUNCT
dpc-3893	108	37	especially	especially	ADV
dpc-3893	108	38	located	locate	VERB
dpc-3893	108	39	on	on	ADP
dpc-3893	108	40	acral	acral	ADJ
dpc-3893	108	41	areas	area	NOUN
dpc-3893	108	42	or	or	CCONJ
dpc-3893	108	43	in	in	ADP
dpc-3893	108	44	areas	area	NOUN
dpc-3893	108	45	with	with	ADP
dpc-3893	108	46	poliosis	poliosis	PROPN
dpc-3893	108	47	[	[	X
dpc-3893	108	48	36	36	NUM
dpc-3893	108	49	]	]	PUNCT
dpc-3893	108	50	.	.	PUNCT
dpc-3893	109	1	in	in	ADP
dpc-3893	109	2	this	this	DET
dpc-3893	109	3	line	line	NOUN
dpc-3893	109	4	,	,	PUNCT
dpc-3893	109	5	the	the	DET
dpc-3893	109	6	wnt	wnt	NOUN
dpc-3893	109	7	signaling	signal	VERB
dpc-3893	109	8	,	,	PUNCT
dpc-3893	109	9	which	which	PRON
dpc-3893	109	10	is	be	AUX
dpc-3893	109	11	repressed	repress	VERB
dpc-3893	109	12	in	in	ADP
dpc-3893	109	13	depigmented	depigmented	ADJ
dpc-3893	109	14	skin	skin	NOUN
dpc-3893	109	15	of	of	ADP
dpc-3893	109	16	vitiligo	vitiligo	ADJ
dpc-3893	109	17	patients	patient	NOUN
dpc-3893	109	18	,	,	PUNCT
dpc-3893	109	19	may	may	AUX
dpc-3893	109	20	be	be	AUX
dpc-3893	109	21	an	an	DET
dpc-3893	109	22	important	important	ADJ
dpc-3893	109	23	pathway	pathway	NOUN
dpc-3893	109	24	to	to	PART
dpc-3893	109	25	target	target	VERB
dpc-3893	109	26	to	to	PART
dpc-3893	109	27	induce	induce	VERB
dpc-3893	109	28	melanocyte	melanocyte	NOUN
dpc-3893	109	29	differentiation	differentiation	NOUN
dpc-3893	109	30	.	.	PUNCT
dpc-3893	110	1	conclusion	conclusion	NOUN
dpc-3893	110	2	patients	patient	NOUN
dpc-3893	110	3	with	with	ADP
dpc-3893	110	4	vitiligo	vitiligo	NOUN
dpc-3893	110	5	should	should	AUX
dpc-3893	110	6	be	be	AUX
dpc-3893	110	7	informed	inform	VERB
dpc-3893	110	8	on	on	ADP
dpc-3893	110	9	therapeutic	therapeutic	ADJ
dpc-3893	110	10	options	option	NOUN
dpc-3893	110	11	available	available	ADJ
dpc-3893	110	12	to	to	PART
dpc-3893	110	13	treat	treat	VERB
dpc-3893	110	14	their	their	PRON
dpc-3893	110	15	conditions	condition	NOUN
dpc-3893	110	16	.	.	PUNCT
dpc-3893	111	1	topical	topical	ADJ
dpc-3893	111	2	ruxolitinib	ruxolitinib	NOUN
dpc-3893	111	3	cream	cream	NOUN
dpc-3893	111	4	is	be	AUX
dpc-3893	111	5	now	now	ADV
dpc-3893	111	6	approved	approve	VERB
dpc-3893	111	7	for	for	ADP
dpc-3893	111	8	vitiligo	vitiligo	NOUN
dpc-3893	111	9	and	and	CCONJ
dpc-3893	111	10	this	this	PRON
dpc-3893	111	11	will	will	AUX
dpc-3893	111	12	open	open	VERB
dpc-3893	111	13	the	the	DET
dpc-3893	111	14	development	development	NOUN
dpc-3893	111	15	of	of	ADP
dpc-3893	111	16	other	other	ADJ
dpc-3893	111	17	topical	topical	ADJ
dpc-3893	111	18	and/or	and/or	CCONJ
dpc-3893	111	19	systemic	systemic	ADJ
dpc-3893	111	20	treatments	treatment	NOUN
dpc-3893	111	21	for	for	ADP
dpc-3893	111	22	the	the	DET
dpc-3893	111	23	disease	disease	NOUN
dpc-3893	111	24	.	.	PUNCT
dpc-3893	112	1	it	it	PRON
dpc-3893	112	2	is	be	AUX
dpc-3893	112	3	now	now	ADV
dpc-3893	112	4	important	important	ADJ
dpc-3893	112	5	to	to	PART
dpc-3893	112	6	recognize	recognize	VERB
dpc-3893	112	7	patients	patient	NOUN
dpc-3893	112	8	with	with	ADP
dpc-3893	112	9	progressive	progressive	ADJ
dpc-3893	112	10	disease	disease	NOUN
dpc-3893	112	11	that	that	PRON
dpc-3893	112	12	will	will	AUX
dpc-3893	112	13	require	require	VERB
dpc-3893	112	14	urgent	urgent	ADJ
dpc-3893	112	15	treatment	treatment	NOUN
dpc-3893	112	16	to	to	PART
dpc-3893	112	17	stop	stop	VERB
dpc-3893	112	18	the	the	DET
dpc-3893	112	19	spreading	spreading	NOUN
dpc-3893	112	20	of	of	ADP
dpc-3893	112	21	the	the	DET
dpc-3893	112	22	disease	disease	NOUN
dpc-3893	112	23	.	.	PUNCT
dpc-3893	113	1	references	reference	NOUN
dpc-3893	113	2	1	1	NUM
dpc-3893	113	3	.	.	PUNCT
dpc-3893	113	4	geel	geel	PROPN
dpc-3893	113	5	n	n	CCONJ
dpc-3893	113	6	,	,	PUNCT
dpc-3893	113	7	speeckaert	speeckaert	NOUN
dpc-3893	113	8	r	r	NOUN
dpc-3893	113	9	,	,	PUNCT
dpc-3893	113	10	taïeb	taïeb	NOUN
dpc-3893	113	11	a	a	NOUN
dpc-3893	113	12	,	,	PUNCT
dpc-3893	114	1	et	et	PROPN
dpc-3893	114	2	al	al	PROPN
dpc-3893	114	3	.	.	PROPN
dpc-3893	114	4	worldwide	worldwide	PROPN
dpc-3893	114	5	expert	expert	ADJ
dpc-3893	114	6	recommendations	recommendation	NOUN
dpc-3893	114	7	for	for	ADP
dpc-3893	114	8	the	the	DET
dpc-3893	114	9	diagnosis	diagnosis	NOUN
dpc-3893	114	10	and	and	CCONJ
dpc-3893	114	11	management	management	NOUN
dpc-3893	114	12	of	of	ADP
dpc-3893	114	13	vitiligo	vitiligo	NOUN
dpc-3893	114	14	:	:	PUNCT
dpc-3893	114	15	position	position	NOUN
dpc-3893	114	16	statement	statement	NOUN
dpc-3893	114	17	from	from	ADP
dpc-3893	114	18	the	the	DET
dpc-3893	114	19	international	international	ADJ
dpc-3893	114	20	vitiligo	vitiligo	NOUN
dpc-3893	114	21	task	task	PROPN
dpc-3893	114	22	force	force	NOUN
dpc-3893	114	23	part	part	NOUN
dpc-3893	114	24	1	1	NUM
dpc-3893	114	25	:	:	PUNCT
dpc-3893	114	26	towards	towards	ADP
dpc-3893	114	27	a	a	DET
dpc-3893	114	28	new	new	ADJ
dpc-3893	114	29	management	management	NOUN
dpc-3893	114	30	algorithm	algorithm	NOUN
dpc-3893	114	31	.	.	PUNCT
dpc-3893	115	1	j	j	PROPN
dpc-3893	115	2	eur	eur	PROPN
dpc-3893	115	3	acad	acad	PROPN
dpc-3893	115	4	dermatol	dermatol	NOUN
dpc-3893	115	5	venereol	venereol	NOUN
dpc-3893	115	6	2023	2023	NUM
dpc-3893	115	7	.	.	PUNCT
dpc-3893	116	1	2	2	X
dpc-3893	116	2	.	.	X
dpc-3893	116	3	seneschal	seneschal	PROPN
dpc-3893	116	4	j	j	PROPN
dpc-3893	116	5	,	,	PUNCT
dpc-3893	116	6	speeckaert	speeckaert	NOUN
dpc-3893	116	7	r	r	NOUN
dpc-3893	116	8	,	,	PUNCT
dpc-3893	116	9	taïeb	taïeb	NOUN
dpc-3893	116	10	a	a	NOUN
dpc-3893	116	11	,	,	PUNCT
dpc-3893	116	12	et	et	PROPN
dpc-3893	116	13	al	al	PROPN
dpc-3893	116	14	.	.	PROPN
dpc-3893	116	15	worldwide	worldwide	PROPN
dpc-3893	116	16	expert	expert	ADJ
dpc-3893	116	17	recommendations	recommendation	NOUN
dpc-3893	116	18	for	for	ADP
dpc-3893	116	19	the	the	DET
dpc-3893	116	20	diagnosis	diagnosis	NOUN
dpc-3893	116	21	and	and	CCONJ
dpc-3893	116	22	management	management	NOUN
dpc-3893	116	23	of	of	ADP
dpc-3893	116	24	vitiligo	vitiligo	NOUN
dpc-3893	116	25	:	:	PUNCT
dpc-3893	116	26	position	position	NOUN
dpc-3893	116	27	statement	statement	NOUN
dpc-3893	116	28	from	from	ADP
dpc-3893	116	29	the	the	DET
dpc-3893	116	30	international	international	ADJ
dpc-3893	116	31	vitiligo	vitiligo	NOUN
dpc-3893	116	32	task	task	PROPN
dpc-3893	116	33	force	force	NOUN
dpc-3893	116	34	—	—	PUNCT
dpc-3893	116	35	part	part	NOUN
dpc-3893	116	36	 	 	SPACE
dpc-3893	116	37	2	2	NUM
dpc-3893	116	38	:	:	PUNCT
dpc-3893	116	39	specific	specific	ADJ
dpc-3893	116	40	treatment	treatment	NOUN
dpc-3893	116	41	recommendations	recommendation	NOUN
dpc-3893	116	42	.	.	PUNCT
dpc-3893	117	1	j	j	PROPN
dpc-3893	117	2	eur	eur	PROPN
dpc-3893	117	3	acad	acad	PROPN
dpc-3893	117	4	dermatol	dermatol	NOUN
dpc-3893	117	5	venereol	venereol	NOUN
dpc-3893	117	6	2023	2023	NUM
dpc-3893	117	7	.	.	PUNCT
dpc-3893	118	1	3	3	X
dpc-3893	118	2	.	.	X
dpc-3893	118	3	zhang	zhang	PROPN
dpc-3893	118	4	l	l	PROPN
dpc-3893	118	5	,	,	PUNCT
dpc-3893	118	6	chen	chen	PROPN
dpc-3893	118	7	s	s	PROPN
dpc-3893	118	8	,	,	PUNCT
dpc-3893	118	9	kang	kang	PROPN
dpc-3893	118	10	y	y	PROPN
dpc-3893	118	11	,	,	PUNCT
dpc-3893	118	12	et	et	PROPN
dpc-3893	118	13	al	al	PROPN
dpc-3893	118	14	.	.	PROPN
dpc-3893	118	15	association	association	PROPN
dpc-3893	118	16	of	of	ADP
dpc-3893	118	17	clinical	clinical	ADJ
dpc-3893	118	18	markers	marker	NOUN
dpc-3893	118	19	with	with	ADP
dpc-3893	118	20	disease	disease	NOUN
dpc-3893	118	21	progression	progression	NOUN
dpc-3893	118	22	in	in	ADP
dpc-3893	118	23	patients	patient	NOUN
dpc-3893	118	24	with	with	ADP
dpc-3893	118	25	vitiligo	vitiligo	NOUN
dpc-3893	118	26	from	from	ADP
dpc-3893	118	27	china	china	PROPN
dpc-3893	118	28	.	.	PUNCT
dpc-3893	119	1	jama	jama	PROPN
dpc-3893	119	2	dermatol	dermatol	PROPN
dpc-3893	119	3	2020;156	2020;156	PROPN
dpc-3893	119	4	.	.	PUNCT
dpc-3893	120	1	4	4	NUM
dpc-3893	120	2	.	.	X
dpc-3893	120	3	sosa	sosa	PROPN
dpc-3893	120	4	jj	jj	PROPN
dpc-3893	120	5	,	,	PUNCT
dpc-3893	120	6	currimbhoy	currimbhoy	PROPN
dpc-3893	120	7	sd	sd	PROPN
dpc-3893	120	8	,	,	PUNCT
dpc-3893	120	9	ukoha	ukoha	PROPN
dpc-3893	120	10	u	u	PROPN
dpc-3893	120	11	,	,	PUNCT
dpc-3893	120	12	et	et	PROPN
dpc-3893	120	13	al	al	PROPN
dpc-3893	120	14	.	.	PUNCT
dpc-3893	121	1	confetti	confetti	NOUN
dpc-3893	121	2	-	-	PUNCT
dpc-3893	121	3	like	like	ADJ
dpc-3893	121	4	depigmentation	depigmentation	NOUN
dpc-3893	121	5	:	:	PUNCT
dpc-3893	121	6	a	a	DET
dpc-3893	121	7	potential	potential	ADJ
dpc-3893	121	8	sign	sign	NOUN
dpc-3893	121	9	of	of	ADP
dpc-3893	121	10	rapidly	rapidly	ADV
dpc-3893	121	11	progressing	progress	VERB
dpc-3893	121	12	vitiligo	vitiligo	NOUN
dpc-3893	121	13	.	.	PUNCT
dpc-3893	122	1	j	j	PROPN
dpc-3893	122	2	am	be	AUX
dpc-3893	122	3	acad	acad	ADJ
dpc-3893	122	4	dermatol	dermatol	NOUN
dpc-3893	122	5	2015;73:272–5	2015;73:272–5	NUM
dpc-3893	122	6	.	.	PUNCT
dpc-3893	123	1	4	4	NUM
dpc-3893	123	2	review	review	NOUN
dpc-3893	123	3	|	|	ADV
dpc-3893	123	4	dermatol	dermatol	ADJ
dpc-3893	123	5	pract	pract	NOUN
dpc-3893	123	6	concept	concept	NOUN
dpc-3893	123	7	.	.	PUNCT
dpc-3893	124	1	2023;13(4)s2	2023;13(4)s2	NOUN
dpc-3893	124	2	:	:	PUNCT
dpc-3893	124	3	e2023313s	e2023313s	PROPN
dpc-3893	124	4	21	21	NUM
dpc-3893	124	5	.	.	PUNCT
dpc-3893	125	1	bae	bae	PROPN
dpc-3893	125	2	jm	jm	PROPN
dpc-3893	125	3	,	,	PUNCT
dpc-3893	125	4	ju	ju	PROPN
dpc-3893	125	5	hj	hj	PROPN
dpc-3893	125	6	,	,	PUNCT
dpc-3893	125	7	lee	lee	PROPN
dpc-3893	125	8	rw	rw	PROPN
dpc-3893	125	9	,	,	PUNCT
dpc-3893	125	10	et	et	PROPN
dpc-3893	125	11	al	al	PROPN
dpc-3893	125	12	.	.	PUNCT
dpc-3893	125	13	evaluation	evaluation	NOUN
dpc-3893	125	14	for	for	ADP
dpc-3893	125	15	skin	skin	NOUN
dpc-3893	125	16	cancer	cancer	NOUN
dpc-3893	125	17	and	and	CCONJ
dpc-3893	125	18	precancer	precancer	NOUN
dpc-3893	125	19	in	in	ADP
dpc-3893	125	20	patients	patient	NOUN
dpc-3893	125	21	with	with	ADP
dpc-3893	125	22	vitiligo	vitiligo	PROPN
dpc-3893	125	23	treated	treat	VERB
dpc-3893	125	24	with	with	ADP
dpc-3893	125	25	long	long	ADJ
dpc-3893	125	26	-	-	PUNCT
dpc-3893	125	27	term	term	NOUN
dpc-3893	125	28	narrowband	narrowband	NOUN
dpc-3893	125	29	uv	uv	NOUN
dpc-3893	125	30	-	-	PUNCT
dpc-3893	125	31	b	b	NOUN
dpc-3893	125	32	phototherapy	phototherapy	NOUN
dpc-3893	125	33	.	.	PUNCT
dpc-3893	126	1	jama	jama	PROPN
dpc-3893	126	2	dermatol	dermatol	NOUN
dpc-3893	126	3	2020;156:529–37	2020;156:529–37	PROPN
dpc-3893	126	4	.	.	PUNCT
dpc-3893	127	1	22	22	NUM
dpc-3893	127	2	.	.	PUNCT
dpc-3893	127	3	ju	ju	PROPN
dpc-3893	127	4	hj	hj	PROPN
dpc-3893	127	5	,	,	PUNCT
dpc-3893	127	6	han	han	PROPN
dpc-3893	127	7	jh	jh	PROPN
dpc-3893	127	8	,	,	PUNCT
dpc-3893	127	9	kim	kim	PROPN
dpc-3893	127	10	m	m	PROPN
dpc-3893	127	11	-	-	PUNCT
dpc-3893	127	12	s	s	PROPN
dpc-3893	127	13	,	,	PUNCT
dpc-3893	127	14	et	et	PROPN
dpc-3893	127	15	al	al	PROPN
dpc-3893	127	16	.	.	PUNCT
dpc-3893	128	1	the	the	DET
dpc-3893	128	2	long	long	ADJ
dpc-3893	128	3	-	-	PUNCT
dpc-3893	128	4	term	term	NOUN
dpc-3893	128	5	risk	risk	NOUN
dpc-3893	128	6	of	of	ADP
dpc-3893	128	7	lymphoma	lymphoma	NOUN
dpc-3893	128	8	and	and	CCONJ
dpc-3893	128	9	skin	skin	NOUN
dpc-3893	128	10	cancer	cancer	NOUN
dpc-3893	128	11	was	be	AUX
dpc-3893	128	12	not	not	PART
dpc-3893	128	13	increased	increase	VERB
dpc-3893	128	14	after	after	ADP
dpc-3893	128	15	topical	topical	ADJ
dpc-3893	128	16	calcineurin	calcineurin	NOUN
dpc-3893	128	17	inhibitor	inhibitor	NOUN
dpc-3893	128	18	use	use	NOUN
dpc-3893	128	19	and	and	CCONJ
dpc-3893	128	20	phototherapy	phototherapy	NOUN
dpc-3893	128	21	in	in	ADP
dpc-3893	128	22	a	a	DET
dpc-3893	128	23	cohort	cohort	NOUN
dpc-3893	128	24	of	of	ADP
dpc-3893	128	25	25,694	25,694	NUM
dpc-3893	128	26	patients	patient	NOUN
dpc-3893	128	27	with	with	ADP
dpc-3893	128	28	vitiligo	vitiligo	PROPN
dpc-3893	128	29	.	.	PUNCT
dpc-3893	129	1	j	j	PROPN
dpc-3893	129	2	am	be	AUX
dpc-3893	129	3	acad	acad	ADJ
dpc-3893	129	4	dermatol	dermatol	NOUN
dpc-3893	129	5	2021	2021	NUM
dpc-3893	129	6	.	.	PUNCT
dpc-3893	130	1	23	23	NUM
dpc-3893	130	2	.	.	PUNCT
dpc-3893	131	1	mohammad	mohammad	PROPN
dpc-3893	131	2	tf	tf	PROPN
dpc-3893	131	3	,	,	PUNCT
dpc-3893	131	4	hamzavi	hamzavi	PROPN
dpc-3893	131	5	ih	ih	PRON
dpc-3893	131	6	.	.	PUNCT
dpc-3893	132	1	surgical	surgical	ADJ
dpc-3893	132	2	therapies	therapy	NOUN
dpc-3893	132	3	for	for	ADP
dpc-3893	132	4	vitiligo	vitiligo	NOUN
dpc-3893	132	5	.	.	PUNCT
dpc-3893	133	1	dermatologic	dermatologic	ADJ
dpc-3893	133	2	clinics	clinic	NOUN
dpc-3893	133	3	2017;35:193–203	2017;35:193–203	PROPN
dpc-3893	133	4	.	.	PUNCT
dpc-3893	133	5	24	24	NUM
dpc-3893	133	6	.	.	PUNCT
dpc-3893	133	7	ju	ju	PROPN
dpc-3893	133	8	hj	hj	PROPN
dpc-3893	133	9	,	,	PUNCT
dpc-3893	133	10	bae	bae	PROPN
dpc-3893	133	11	jm	jm	PROPN
dpc-3893	133	12	,	,	PUNCT
dpc-3893	133	13	lee	lee	PROPN
dpc-3893	133	14	rw	rw	PROPN
dpc-3893	133	15	,	,	PUNCT
dpc-3893	133	16	et	et	PROPN
dpc-3893	133	17	al	al	PROPN
dpc-3893	133	18	.	.	PUNCT
dpc-3893	134	1	surgical	surgical	ADJ
dpc-3893	134	2	interventions	intervention	NOUN
dpc-3893	134	3	for	for	ADP
dpc-3893	134	4	patients	patient	NOUN
dpc-3893	134	5	with	with	ADP
dpc-3893	134	6	vitiligo	vitiligo	PROPN
dpc-3893	134	7	.	.	PUNCT
dpc-3893	135	1	jama	jama	PROPN
dpc-3893	135	2	dermatol	dermatol	NOUN
dpc-3893	135	3	2021;157:307–16	2021;157:307–16	NOUN
dpc-3893	135	4	.	.	PROPN
dpc-3893	135	5	25	25	NUM
dpc-3893	135	6	.	.	PUNCT
dpc-3893	136	1	nicolaidou	nicolaidou	PROPN
dpc-3893	136	2	e	e	PROPN
dpc-3893	136	3	,	,	PUNCT
dpc-3893	136	4	antoniou	antoniou	PROPN
dpc-3893	136	5	c	c	PROPN
dpc-3893	136	6	,	,	PUNCT
dpc-3893	136	7	stratigos	stratigos	PROPN
dpc-3893	136	8	aj	aj	PROPN
dpc-3893	136	9	,	,	PUNCT
dpc-3893	136	10	stefanaki	stefanaki	PROPN
dpc-3893	136	11	c	c	PROPN
dpc-3893	136	12	,	,	PUNCT
dpc-3893	136	13	katsambas	katsambas	PROPN
dpc-3893	136	14	ad	ad	NOUN
dpc-3893	136	15	.	.	PUNCT
dpc-3893	137	1	efficacy	efficacy	NOUN
dpc-3893	137	2	,	,	PUNCT
dpc-3893	137	3	predictors	predictor	NOUN
dpc-3893	137	4	of	of	ADP
dpc-3893	137	5	response	response	NOUN
dpc-3893	137	6	,	,	PUNCT
dpc-3893	137	7	and	and	CCONJ
dpc-3893	137	8	long	long	ADJ
dpc-3893	137	9	-	-	PUNCT
dpc-3893	137	10	term	term	NOUN
dpc-3893	137	11	follow	follow	NOUN
dpc-3893	137	12	-	-	PUNCT
dpc-3893	137	13	up	up	NOUN
dpc-3893	137	14	in	in	ADP
dpc-3893	137	15	patients	patient	NOUN
dpc-3893	137	16	with	with	ADP
dpc-3893	137	17	vitiligo	vitiligo	PROPN
dpc-3893	137	18	treated	treat	VERB
dpc-3893	137	19	with	with	ADP
dpc-3893	137	20	narrowband	narrowband	NOUN
dpc-3893	137	21	uvb	uvb	ADJ
dpc-3893	137	22	phototherapy	phototherapy	NOUN
dpc-3893	137	23	.	.	PUNCT
dpc-3893	138	1	j	j	PROPN
dpc-3893	138	2	am	be	AUX
dpc-3893	138	3	acad	acad	ADJ
dpc-3893	138	4	dermatol	dermatol	NOUN
dpc-3893	138	5	2007;56:274–8	2007;56:274–8	NUM
dpc-3893	138	6	.	.	PUNCT
dpc-3893	139	1	26	26	NUM
dpc-3893	139	2	.	.	X
dpc-3893	139	3	cavalié	cavalié	PROPN
dpc-3893	139	4	m	m	PROPN
dpc-3893	139	5	,	,	PUNCT
dpc-3893	139	6	ezzedine	ezzedine	PROPN
dpc-3893	139	7	k	k	NOUN
dpc-3893	139	8	,	,	PUNCT
dpc-3893	139	9	fontas	fonta	NOUN
dpc-3893	139	10	e	e	NOUN
dpc-3893	139	11	,	,	PUNCT
dpc-3893	139	12	et	et	PROPN
dpc-3893	139	13	al	al	PROPN
dpc-3893	139	14	.	.	PUNCT
dpc-3893	139	15	maintenance	maintenance	NOUN
dpc-3893	139	16	therapy	therapy	NOUN
dpc-3893	139	17	of	of	ADP
dpc-3893	139	18	adult	adult	NOUN
dpc-3893	139	19	vitiligo	vitiligo	NOUN
dpc-3893	139	20	with	with	ADP
dpc-3893	139	21	0.1	0.1	NUM
dpc-3893	139	22	%	%	NOUN
dpc-3893	139	23	tacrolimus	tacrolimus	NOUN
dpc-3893	139	24	ointment	ointment	NOUN
dpc-3893	139	25	:	:	PUNCT
dpc-3893	139	26	a	a	DET
dpc-3893	139	27	randomized	randomized	ADJ
dpc-3893	139	28	,	,	PUNCT
dpc-3893	139	29	double	double	ADV
dpc-3893	139	30	blind	blind	ADJ
dpc-3893	139	31	,	,	PUNCT
dpc-3893	139	32	placebo	placebo	NOUN
dpc-3893	139	33	-	-	PUNCT
dpc-3893	139	34	controlled	control	VERB
dpc-3893	139	35	study	study	NOUN
dpc-3893	139	36	.	.	PUNCT
dpc-3893	140	1	the	the	DET
dpc-3893	140	2	journal	journal	NOUN
dpc-3893	140	3	of	of	ADP
dpc-3893	140	4	investigative	investigative	ADJ
dpc-3893	140	5	dermatology	dermatology	NOUN
dpc-3893	140	6	2015;135:970–4	2015;135:970–4	NUM
dpc-3893	140	7	.	.	PUNCT
dpc-3893	141	1	27	27	NUM
dpc-3893	141	2	.	.	PUNCT
dpc-3893	142	1	komen	komen	PROPN
dpc-3893	142	2	l	l	NOUN
dpc-3893	142	3	,	,	PUNCT
dpc-3893	142	4	zwertbroek	zwertbroek	PROPN
dpc-3893	142	5	l	l	NOUN
dpc-3893	142	6	,	,	PUNCT
dpc-3893	142	7	burger	burger	NOUN
dpc-3893	142	8	sj	sj	PROPN
dpc-3893	142	9	,	,	PUNCT
dpc-3893	142	10	veen	veen	PROPN
dpc-3893	142	11	jpw	jpw	PROPN
dpc-3893	142	12	,	,	PUNCT
dpc-3893	142	13	rie	rie	PROPN
dpc-3893	142	14	ma	ma	PROPN
dpc-3893	142	15	,	,	PUNCT
dpc-3893	142	16	wolkerstorfer	wolkerstorfer	ADJ
dpc-3893	142	17	a.	a.	NOUN
dpc-3893	142	18	q‐switched	q‐switched	PUNCT
dpc-3893	142	19	laser	laser	NOUN
dpc-3893	142	20	depigmentation	depigmentation	NOUN
dpc-3893	142	21	in	in	ADP
dpc-3893	142	22	vitiligo	vitiligo	NOUN
dpc-3893	142	23	,	,	PUNCT
dpc-3893	142	24	most	most	ADV
dpc-3893	142	25	effective	effective	ADJ
dpc-3893	142	26	in	in	ADP
dpc-3893	142	27	active	active	ADJ
dpc-3893	142	28	disease	disease	NOUN
dpc-3893	142	29	.	.	PUNCT
dpc-3893	143	1	brit	brit	PROPN
dpc-3893	143	2	j	j	PROPN
dpc-3893	144	1	dermatol	dermatol	ADJ
dpc-3893	144	2	2013;169:1246–51	2013;169:1246–51	NUM
dpc-3893	144	3	.	.	PUNCT
dpc-3893	144	4	28	28	NUM
dpc-3893	144	5	.	.	PUNCT
dpc-3893	145	1	mosher	mosher	PROPN
dpc-3893	145	2	db	db	PROPN
dpc-3893	145	3	,	,	PUNCT
dpc-3893	145	4	parrish	parrish	PROPN
dpc-3893	145	5	ja	ja	PROPN
dpc-3893	145	6	,	,	PUNCT
dpc-3893	145	7	fitzpatrick	fitzpatrick	PROPN
dpc-3893	145	8	tb	tb	PROPN
dpc-3893	145	9	.	.	PROPN
dpc-3893	145	10	monobenzylether	monobenzylether	PROPN
dpc-3893	145	11	of	of	ADP
dpc-3893	145	12	hydroquinone	hydroquinone	PROPN
dpc-3893	145	13	.	.	PUNCT
dpc-3893	146	1	brit	brit	PROPN
dpc-3893	146	2	j	j	PROPN
dpc-3893	146	3	dermatol	dermatol	NOUN
dpc-3893	146	4	1977;97:669–79	1977;97:669–79	PROPN
dpc-3893	146	5	.	.	PROPN
dpc-3893	146	6	29	29	NUM
dpc-3893	146	7	.	.	PUNCT
dpc-3893	147	1	ezzedine	ezzedine	PROPN
dpc-3893	147	2	k	k	PROPN
dpc-3893	147	3	,	,	PUNCT
dpc-3893	147	4	peeva	peeva	PROPN
dpc-3893	147	5	e	e	PROPN
dpc-3893	147	6	,	,	PUNCT
dpc-3893	147	7	yamaguchi	yamaguchi	PROPN
dpc-3893	147	8	y	y	PROPN
dpc-3893	147	9	,	,	PUNCT
dpc-3893	147	10	et	et	PROPN
dpc-3893	147	11	al	al	PROPN
dpc-3893	147	12	.	.	PROPN
dpc-3893	147	13	efficacy	efficacy	NOUN
dpc-3893	147	14	and	and	CCONJ
dpc-3893	147	15	safety	safety	NOUN
dpc-3893	147	16	of	of	ADP
dpc-3893	147	17	oral	oral	ADJ
dpc-3893	147	18	ritlecitinib	ritlecitinib	NOUN
dpc-3893	147	19	for	for	ADP
dpc-3893	147	20	the	the	DET
dpc-3893	147	21	treatment	treatment	NOUN
dpc-3893	147	22	of	of	ADP
dpc-3893	147	23	active	active	ADJ
dpc-3893	147	24	nonsegmental	nonsegmental	NOUN
dpc-3893	147	25	vitiligo	vitiligo	VERB
dpc-3893	147	26	:	:	PUNCT
dpc-3893	147	27	a	a	DET
dpc-3893	147	28	randomized	randomized	ADJ
dpc-3893	147	29	phase	phase	NOUN
dpc-3893	147	30	2b	2b	NUM
dpc-3893	147	31	clinical	clinical	ADJ
dpc-3893	147	32	trial	trial	NOUN
dpc-3893	147	33	.	.	PUNCT
dpc-3893	148	1	j	j	PROPN
dpc-3893	148	2	am	be	AUX
dpc-3893	148	3	acad	acad	ADJ
dpc-3893	148	4	dermatol	dermatol	NOUN
dpc-3893	148	5	2023;88:395–403	2023;88:395–403	NOUN
dpc-3893	148	6	.	.	PUNCT
dpc-3893	149	1	30	30	NUM
dpc-3893	149	2	.	.	PUNCT
dpc-3893	150	1	richmond	richmond	PROPN
dpc-3893	150	2	jm	jm	PROPN
dpc-3893	150	3	,	,	PUNCT
dpc-3893	150	4	strassner	strassner	PROPN
dpc-3893	150	5	jp	jp	PROPN
dpc-3893	150	6	,	,	PUNCT
dpc-3893	150	7	zapata	zapata	PROPN
dpc-3893	150	8	l	l	PROPN
dpc-3893	150	9	,	,	PUNCT
dpc-3893	150	10	et	et	PROPN
dpc-3893	150	11	al	al	PROPN
dpc-3893	150	12	.	.	PUNCT
dpc-3893	150	13	antibody	antibody	NOUN
dpc-3893	150	14	blockade	blockade	NOUN
dpc-3893	150	15	of	of	ADP
dpc-3893	150	16	il-15	il-15	NOUN
dpc-3893	150	17	signaling	signal	VERB
dpc-3893	150	18	has	have	VERB
dpc-3893	150	19	the	the	DET
dpc-3893	150	20	potential	potential	NOUN
dpc-3893	150	21	to	to	PART
dpc-3893	150	22	durably	durably	ADV
dpc-3893	150	23	reverse	reverse	VERB
dpc-3893	150	24	vitiligo	vitiligo	NOUN
dpc-3893	150	25	.	.	PUNCT
dpc-3893	151	1	sci	sci	PROPN
dpc-3893	151	2	transl	transl	PROPN
dpc-3893	151	3	med	med	PROPN
dpc-3893	151	4	2018;10	2018;10	NOUN
dpc-3893	151	5	:	:	PUNCT
dpc-3893	151	6	eaam7710	eaam7710	ADJ
dpc-3893	151	7	.	.	PUNCT
dpc-3893	152	1	31	31	NUM
dpc-3893	152	2	.	.	PUNCT
dpc-3893	153	1	jacquemin	jacquemin	PROPN
dpc-3893	153	2	c	c	PROPN
dpc-3893	153	3	,	,	PUNCT
dpc-3893	153	4	rambert	rambert	PROPN
dpc-3893	153	5	j	j	PROPN
dpc-3893	153	6	,	,	PUNCT
dpc-3893	153	7	guillet	guillet	VERB
dpc-3893	153	8	s	s	PROPN
dpc-3893	153	9	,	,	PUNCT
dpc-3893	153	10	et	et	PROPN
dpc-3893	153	11	al	al	PROPN
dpc-3893	153	12	.	.	PROPN
dpc-3893	153	13	heat	heat	NOUN
dpc-3893	153	14	shock	shock	NOUN
dpc-3893	153	15	protein	protein	NOUN
dpc-3893	153	16	70	70	NUM
dpc-3893	153	17	 	 	SPACE
dpc-3893	153	18	potentiates	potentiate	VERB
dpc-3893	153	19	interferon	interferon	ADJ
dpc-3893	153	20	alpha	alpha	NOUN
dpc-3893	153	21	production	production	NOUN
dpc-3893	153	22	by	by	ADP
dpc-3893	153	23	plasmacytoid	plasmacytoid	NOUN
dpc-3893	153	24	dendritic	dendritic	ADJ
dpc-3893	153	25	cells	cell	NOUN
dpc-3893	153	26	:	:	PUNCT
dpc-3893	154	1	relevance	relevance	NOUN
dpc-3893	154	2	for	for	ADP
dpc-3893	154	3	cutaneous	cutaneous	ADJ
dpc-3893	154	4	lupus	lupus	NOUN
dpc-3893	154	5	and	and	CCONJ
dpc-3893	154	6	vitiligo	vitiligo	ADJ
dpc-3893	154	7	pathogenesis	pathogenesis	NOUN
dpc-3893	154	8	.	.	PUNCT
dpc-3893	155	1	the	the	DET
dpc-3893	155	2	british	british	ADJ
dpc-3893	155	3	journal	journal	PROPN
dpc-3893	155	4	of	of	ADP
dpc-3893	155	5	dermatology	dermatology	NOUN
dpc-3893	155	6	2017;177:1367–75	2017;177:1367–75	NOUN
dpc-3893	155	7	.	.	PUNCT
dpc-3893	156	1	32	32	NUM
dpc-3893	156	2	.	.	PUNCT
dpc-3893	157	1	mosenson	mosenson	PROPN
dpc-3893	157	2	ja	ja	PROPN
dpc-3893	157	3	,	,	PUNCT
dpc-3893	157	4	eby	eby	PROPN
dpc-3893	157	5	jm	jm	PROPN
dpc-3893	157	6	,	,	PUNCT
dpc-3893	157	7	hernandez	hernandez	PROPN
dpc-3893	157	8	c	c	PROPN
dpc-3893	157	9	,	,	PUNCT
dpc-3893	157	10	poole	poole	PROPN
dpc-3893	157	11	icl	icl	PROPN
dpc-3893	157	12	.	.	PUNCT
dpc-3893	158	1	a	a	DET
dpc-3893	158	2	central	central	ADJ
dpc-3893	158	3	role	role	NOUN
dpc-3893	158	4	for	for	ADP
dpc-3893	158	5	inducible	inducible	ADJ
dpc-3893	158	6	heat	heat	NOUN
dpc-3893	158	7	-	-	PUNCT
dpc-3893	158	8	shock	shock	NOUN
dpc-3893	158	9	protein	protein	NOUN
dpc-3893	158	10	70	70	NUM
dpc-3893	158	11	in	in	ADP
dpc-3893	158	12	autoimmune	autoimmune	ADJ
dpc-3893	158	13	vitiligo	vitiligo	NOUN
dpc-3893	158	14	.	.	PUNCT
dpc-3893	159	1	experimental	experimental	ADJ
dpc-3893	159	2	dermatology	dermatology	NOUN
dpc-3893	159	3	2013;22:566–9	2013;22:566–9	NUM
dpc-3893	159	4	.	.	PUNCT
dpc-3893	160	1	33	33	NUM
dpc-3893	160	2	.	.	PUNCT
dpc-3893	161	1	mosenson	mosenson	PROPN
dpc-3893	161	2	ja	ja	PROPN
dpc-3893	161	3	,	,	PUNCT
dpc-3893	161	4	zloza	zloza	PROPN
dpc-3893	161	5	a	a	PRON
dpc-3893	161	6	,	,	PUNCT
dpc-3893	161	7	nieland	nieland	PROPN
dpc-3893	161	8	jd	jd	PROPN
dpc-3893	161	9	,	,	PUNCT
dpc-3893	161	10	et	et	PROPN
dpc-3893	161	11	al	al	PROPN
dpc-3893	161	12	.	.	PROPN
dpc-3893	162	1	mutant	mutant	PROPN
dpc-3893	162	2	hsp70	hsp70	PROPN
dpc-3893	162	3	reverses	reverse	VERB
dpc-3893	162	4	autoimmune	autoimmune	ADJ
dpc-3893	162	5	depigmentation	depigmentation	NOUN
dpc-3893	162	6	in	in	ADP
dpc-3893	162	7	vitiligo	vitiligo	PROPN
dpc-3893	162	8	.	.	PUNCT
dpc-3893	163	1	science	science	PROPN
dpc-3893	163	2	translational	translational	ADJ
dpc-3893	163	3	medicine	medicine	NOUN
dpc-3893	163	4	2013;5:174ra28	2013;5:174ra28	PROPN
dpc-3893	163	5	-	-	SYM
dpc-3893	163	6	174ra28	174ra28	NUM
dpc-3893	163	7	.	.	PUNCT
dpc-3893	164	1	34	34	NUM
dpc-3893	164	2	.	.	PUNCT
dpc-3893	164	3	boukhedouni	boukhedouni	PROPN
dpc-3893	164	4	n	n	CCONJ
dpc-3893	164	5	,	,	PUNCT
dpc-3893	164	6	martins	martin	VERB
dpc-3893	164	7	c	c	NUM
dpc-3893	164	8	,	,	PUNCT
dpc-3893	164	9	darrigade	darrigade	VERB
dpc-3893	164	10	a	a	DET
dpc-3893	164	11	-	-	PUNCT
dpc-3893	164	12	s	s	NOUN
dpc-3893	164	13	,	,	PUNCT
dpc-3893	164	14	et	et	PROPN
dpc-3893	164	15	al	al	PROPN
dpc-3893	164	16	.	.	PUNCT
dpc-3893	165	1	type-1	type-1	PRON
dpc-3893	165	2	cytokines	cytokine	VERB
dpc-3893	165	3	regulate	regulate	VERB
dpc-3893	165	4	matrix	matrix	NOUN
dpc-3893	165	5	metalloprotease-9	metalloprotease-9	NOUN
dpc-3893	165	6	production	production	NOUN
dpc-3893	165	7	and	and	CCONJ
dpc-3893	165	8	e	e	NOUN
dpc-3893	165	9	-	-	NOUN
dpc-3893	165	10	cadherin	cadherin	NOUN
dpc-3893	165	11	disruption	disruption	NOUN
dpc-3893	165	12	to	to	PART
dpc-3893	165	13	promote	promote	VERB
dpc-3893	165	14	melanocyte	melanocyte	NOUN
dpc-3893	165	15	loss	loss	NOUN
dpc-3893	165	16	in	in	ADP
dpc-3893	165	17	vitiligo	vitiligo	PROPN
dpc-3893	165	18	.	.	PUNCT
dpc-3893	166	1	jci	jci	PROPN
dpc-3893	166	2	insight	insight	PROPN
dpc-3893	166	3	2020	2020	NUM
dpc-3893	166	4	.	.	PUNCT
dpc-3893	167	1	35	35	NUM
dpc-3893	167	2	.	.	PUNCT
dpc-3893	168	1	bzioueche	bzioueche	PROPN
dpc-3893	168	2	h	h	PROPN
dpc-3893	168	3	,	,	PUNCT
dpc-3893	168	4	sjödin	sjödin	PROPN
dpc-3893	168	5	ks	ks	PROPN
dpc-3893	168	6	,	,	PUNCT
dpc-3893	168	7	west	west	PROPN
dpc-3893	168	8	ce	ce	PROPN
dpc-3893	168	9	,	,	PUNCT
dpc-3893	168	10	et	et	PROPN
dpc-3893	168	11	al	al	PROPN
dpc-3893	168	12	.	.	PUNCT
dpc-3893	168	13	analysis	analysis	NOUN
dpc-3893	168	14	of	of	ADP
dpc-3893	168	15	matched	match	VERB
dpc-3893	168	16	skin	skin	NOUN
dpc-3893	168	17	and	and	CCONJ
dpc-3893	168	18	gut	gut	NOUN
dpc-3893	168	19	microbiome	microbiome	NOUN
dpc-3893	168	20	of	of	ADP
dpc-3893	168	21	patients	patient	NOUN
dpc-3893	168	22	with	with	ADP
dpc-3893	168	23	vitiligo	vitiligo	PROPN
dpc-3893	168	24	reveals	reveal	VERB
dpc-3893	168	25	deep	deep	ADJ
dpc-3893	168	26	skin	skin	NOUN
dpc-3893	168	27	dysbiosis	dysbiosis	NOUN
dpc-3893	168	28	:	:	PUNCT
dpc-3893	168	29	link	link	VERB
dpc-3893	168	30	with	with	ADP
dpc-3893	168	31	mitochondrial	mitochondrial	ADJ
dpc-3893	168	32	and	and	CCONJ
dpc-3893	168	33	immune	immune	ADJ
dpc-3893	168	34	changes	change	NOUN
dpc-3893	168	35	.	.	PUNCT
dpc-3893	169	1	j	j	PROPN
dpc-3893	169	2	invest	invest	VERB
dpc-3893	169	3	dermatol	dermatol	NOUN
dpc-3893	169	4	2021;141:2280–90	2021;141:2280–90	NOUN
dpc-3893	169	5	.	.	PUNCT
dpc-3893	170	1	36	36	NUM
dpc-3893	170	2	.	.	PUNCT
dpc-3893	171	1	regazzetti	regazzetti	VERB
dpc-3893	171	2	c	c	X
dpc-3893	171	3	,	,	PUNCT
dpc-3893	171	4	joly	joly	PROPN
dpc-3893	171	5	f	f	PROPN
dpc-3893	171	6	,	,	PUNCT
dpc-3893	171	7	marty	marty	PROPN
dpc-3893	171	8	c	c	AUX
dpc-3893	171	9	,	,	PUNCT
dpc-3893	171	10	et	et	PROPN
dpc-3893	171	11	al	al	PROPN
dpc-3893	171	12	.	.	PUNCT
dpc-3893	172	1	transcriptional	transcriptional	ADJ
dpc-3893	172	2	analysis	analysis	NOUN
dpc-3893	172	3	of	of	ADP
dpc-3893	172	4	vitiligo	vitiligo	ADJ
dpc-3893	172	5	skin	skin	NOUN
dpc-3893	172	6	reveals	reveal	VERB
dpc-3893	172	7	the	the	DET
dpc-3893	172	8	alteration	alteration	NOUN
dpc-3893	172	9	of	of	ADP
dpc-3893	172	10	wnt	wnt	PROPN
dpc-3893	172	11	pathway	pathway	NOUN
dpc-3893	172	12	:	:	PUNCT
dpc-3893	172	13	a	a	DET
dpc-3893	172	14	promising	promising	ADJ
dpc-3893	172	15	target	target	NOUN
dpc-3893	172	16	for	for	ADP
dpc-3893	172	17	repigmenting	repigmente	VERB
dpc-3893	172	18	vitiligo	vitiligo	NOUN
dpc-3893	172	19	patients	patient	NOUN
dpc-3893	172	20	.	.	PUNCT
dpc-3893	173	1	j	j	PROPN
dpc-3893	173	2	invest	invest	VERB
dpc-3893	173	3	dermatol	dermatol	NOUN
dpc-3893	173	4	2015;135:3105–14	2015;135:3105–14	NUM
dpc-3893	173	5	.	.	PUNCT
dpc-3893	174	1	5	5	NUM
dpc-3893	174	2	.	.	X
dpc-3893	174	3	geel	geel	PROPN
dpc-3893	174	4	n	n	PROPN
dpc-3893	174	5	van	van	PROPN
dpc-3893	174	6	,	,	PUNCT
dpc-3893	174	7	speeckaert	speeckaert	NOUN
dpc-3893	174	8	r	r	NOUN
dpc-3893	174	9	,	,	PUNCT
dpc-3893	174	10	wolf	wolf	PROPN
dpc-3893	174	11	jd	jd	PROPN
dpc-3893	174	12	,	,	PUNCT
dpc-3893	174	13	et	et	PROPN
dpc-3893	174	14	al	al	PROPN
dpc-3893	174	15	.	.	PROPN
dpc-3893	175	1	clinical	clinical	ADJ
dpc-3893	175	2	significance	significance	NOUN
dpc-3893	175	3	of	of	ADP
dpc-3893	175	4	koebner	koebner	NOUN
dpc-3893	175	5	phenomenon	phenomenon	NOUN
dpc-3893	175	6	in	in	ADP
dpc-3893	175	7	vitiligo	vitiligo	PROPN
dpc-3893	175	8	.	.	PUNCT
dpc-3893	176	1	brit	brit	PROPN
dpc-3893	176	2	j	j	PROPN
dpc-3893	176	3	dermatol	dermatol	NOUN
dpc-3893	176	4	2012;167:1017–24	2012;167:1017–24	NUM
dpc-3893	176	5	.	.	PROPN
dpc-3893	177	1	6	6	NUM
dpc-3893	177	2	.	.	X
dpc-3893	177	3	geel	geel	PROPN
dpc-3893	177	4	n	n	PROPN
dpc-3893	177	5	van	van	PROPN
dpc-3893	177	6	,	,	PUNCT
dpc-3893	177	7	grine	grine	PROPN
dpc-3893	177	8	l	l	PROPN
dpc-3893	177	9	,	,	PUNCT
dpc-3893	177	10	wispelaere	wispelaere	ADJ
dpc-3893	177	11	pd	pd	PROPN
dpc-3893	177	12	,	,	PUNCT
dpc-3893	177	13	mertens	mertens	PROPN
dpc-3893	177	14	d	d	PROPN
dpc-3893	177	15	,	,	PUNCT
dpc-3893	177	16	prinsen	prinsen	PROPN
dpc-3893	177	17	cac	cac	PROPN
dpc-3893	177	18	,	,	PUNCT
dpc-3893	177	19	speeckaert	speeckaert	PROPN
dpc-3893	177	20	r.	r.	PROPN
dpc-3893	177	21	clinical	clinical	ADJ
dpc-3893	177	22	visible	visible	ADJ
dpc-3893	177	23	signs	sign	NOUN
dpc-3893	177	24	of	of	ADP
dpc-3893	177	25	disease	disease	NOUN
dpc-3893	177	26	activity	activity	NOUN
dpc-3893	177	27	in	in	ADP
dpc-3893	177	28	vitiligo	vitiligo	NOUN
dpc-3893	177	29	:	:	PUNCT
dpc-3893	177	30	a	a	DET
dpc-3893	177	31	systematic	systematic	ADJ
dpc-3893	177	32	review	review	NOUN
dpc-3893	177	33	and	and	CCONJ
dpc-3893	177	34	meta‐analysis	meta‐analysis	NOUN
dpc-3893	177	35	.	.	PUNCT
dpc-3893	178	1	j	j	PROPN
dpc-3893	178	2	eur	eur	PROPN
dpc-3893	178	3	acad	acad	PROPN
dpc-3893	178	4	dermatol	dermatol	NOUN
dpc-3893	178	5	venereol	venereol	NOUN
dpc-3893	178	6	2019;33:1667–75doi:10.1111	2019;33:1667–75doi:10.1111	NUM
dpc-3893	178	7	/	/	SYM
dpc-3893	178	8	jdv.15604	jdv.15604	PROPN
dpc-3893	178	9	.	.	PUNCT
dpc-3893	179	1	7	7	X
dpc-3893	179	2	.	.	X
dpc-3893	179	3	geel	geel	PROPN
dpc-3893	179	4	n	n	PROPN
dpc-3893	179	5	van	van	PROPN
dpc-3893	179	6	,	,	PUNCT
dpc-3893	179	7	passeron	passeron	PROPN
dpc-3893	179	8	t	t	PROPN
dpc-3893	179	9	,	,	PUNCT
dpc-3893	179	10	wolkerstorfer	wolkerstorfer	VERB
dpc-3893	179	11	a	a	DET
dpc-3893	179	12	,	,	PUNCT
dpc-3893	179	13	speeckaert	speeckaert	NOUN
dpc-3893	179	14	r	r	NOUN
dpc-3893	179	15	,	,	PUNCT
dpc-3893	179	16	ezzedine	ezzedine	NOUN
dpc-3893	179	17	k.	k.	NOUN
dpc-3893	179	18	reliability	reliability	PROPN
dpc-3893	179	19	and	and	CCONJ
dpc-3893	179	20	validity	validity	NOUN
dpc-3893	179	21	of	of	ADP
dpc-3893	179	22	the	the	DET
dpc-3893	179	23	vitiligo	vitiligo	ADJ
dpc-3893	179	24	signs	sign	NOUN
dpc-3893	179	25	of	of	ADP
dpc-3893	179	26	activity	activity	NOUN
dpc-3893	179	27	score	score	NOUN
dpc-3893	179	28	(	(	PUNCT
dpc-3893	179	29	vsas	vsa	NOUN
dpc-3893	179	30	)	)	PUNCT
dpc-3893	179	31	.	.	PUNCT
dpc-3893	180	1	brit	brit	PROPN
dpc-3893	180	2	j	j	PROPN
dpc-3893	180	3	dermatol	dermatol	NOUN
dpc-3893	180	4	2020	2020	NUM
dpc-3893	180	5	.	.	PUNCT
dpc-3893	181	1	8	8	X
dpc-3893	181	2	.	.	X
dpc-3893	181	3	passeron	passeron	PROPN
dpc-3893	181	4	t.	t.	PROPN
dpc-3893	181	5	medical	medical	ADJ
dpc-3893	181	6	and	and	CCONJ
dpc-3893	181	7	maintenance	maintenance	NOUN
dpc-3893	181	8	treatments	treatment	NOUN
dpc-3893	181	9	for	for	ADP
dpc-3893	181	10	vitiligo	vitiligo	NOUN
dpc-3893	181	11	.	.	PUNCT
dpc-3893	182	1	dermatol	dermatol	NOUN
dpc-3893	182	2	clin	clin	PROPN
dpc-3893	182	3	2017;35:163–70	2017;35:163–70	PROPN
dpc-3893	182	4	.	.	PUNCT
dpc-3893	183	1	9	9	NUM
dpc-3893	183	2	.	.	X
dpc-3893	183	3	tovar	tovar	PROPN
dpc-3893	183	4	-	-	PUNCT
dpc-3893	183	5	garza	garza	PROPN
dpc-3893	183	6	a	a	X
dpc-3893	183	7	,	,	PUNCT
dpc-3893	183	8	hinojosa	hinojosa	PROPN
dpc-3893	183	9	ja	ja	PROPN
dpc-3893	183	10	,	,	PUNCT
dpc-3893	183	11	hynan	hynan	PROPN
dpc-3893	183	12	ls	ls	PROPN
dpc-3893	183	13	,	,	PUNCT
dpc-3893	183	14	pandya	pandya	PROPN
dpc-3893	183	15	ag	ag	PROPN
dpc-3893	183	16	.	.	PROPN
dpc-3893	184	1	addition	addition	NOUN
dpc-3893	184	2	of	of	ADP
dpc-3893	184	3	oral	oral	ADJ
dpc-3893	184	4	minipulse	minipulse	NOUN
dpc-3893	184	5	dexamethasone	dexamethasone	NOUN
dpc-3893	184	6	to	to	PART
dpc-3893	184	7	narrowband	narrowband	VERB
dpc-3893	184	8	ultraviolet	ultraviolet	PROPN
dpc-3893	184	9	b	b	PROPN
dpc-3893	184	10	phototherapy	phototherapy	NOUN
dpc-3893	184	11	and	and	CCONJ
dpc-3893	184	12	topical	topical	ADJ
dpc-3893	184	13	steroids	steroid	NOUN
dpc-3893	184	14	helps	help	VERB
dpc-3893	184	15	arrest	arrest	VERB
dpc-3893	184	16	disease	disease	NOUN
dpc-3893	184	17	activity	activity	NOUN
dpc-3893	184	18	in	in	ADP
dpc-3893	184	19	patients	patient	NOUN
dpc-3893	184	20	with	with	ADP
dpc-3893	184	21	vitiligo	vitiligo	NOUN
dpc-3893	184	22	.	.	PUNCT
dpc-3893	185	1	the	the	DET
dpc-3893	185	2	british	british	ADJ
dpc-3893	185	3	journal	journal	PROPN
dpc-3893	185	4	of	of	ADP
dpc-3893	185	5	dermatology	dermatology	NOUN
dpc-3893	185	6	2019;180:193–4	2019;180:193–4	NUM
dpc-3893	185	7	.	.	PUNCT
dpc-3893	186	1	10	10	NUM
dpc-3893	186	2	.	.	PUNCT
dpc-3893	187	1	passeron	passeron	PROPN
dpc-3893	187	2	t	t	PROPN
dpc-3893	187	3	,	,	PUNCT
dpc-3893	187	4	ostovari	ostovari	NOUN
dpc-3893	187	5	n	n	CCONJ
dpc-3893	187	6	,	,	PUNCT
dpc-3893	187	7	zakaria	zakaria	PROPN
dpc-3893	187	8	w	w	PROPN
dpc-3893	187	9	,	,	PUNCT
dpc-3893	187	10	et	et	PROPN
dpc-3893	187	11	al	al	PROPN
dpc-3893	187	12	.	.	PUNCT
dpc-3893	187	13	topical	topical	ADJ
dpc-3893	187	14	tacrolimus	tacrolimus	NOUN
dpc-3893	187	15	and	and	CCONJ
dpc-3893	187	16	the	the	DET
dpc-3893	187	17	308	308	NUM
dpc-3893	187	18	-	-	PUNCT
dpc-3893	187	19	nm	nm	ADJ
dpc-3893	187	20	excimer	excimer	NOUN
dpc-3893	187	21	laser	laser	NOUN
dpc-3893	187	22	:	:	PUNCT
dpc-3893	187	23	a	a	DET
dpc-3893	187	24	synergistic	synergistic	ADJ
dpc-3893	187	25	combination	combination	NOUN
dpc-3893	187	26	for	for	ADP
dpc-3893	187	27	the	the	DET
dpc-3893	187	28	treatment	treatment	NOUN
dpc-3893	187	29	of	of	ADP
dpc-3893	187	30	vitiligo	vitiligo	NOUN
dpc-3893	187	31	.	.	PUNCT
dpc-3893	188	1	arch	arch	ADJ
dpc-3893	188	2	dermatol	dermatol	NOUN
dpc-3893	188	3	2004;140:1065–9	2004;140:1065–9	NOUN
dpc-3893	188	4	.	.	PUNCT
dpc-3893	189	1	11	11	NUM
dpc-3893	189	2	.	.	PUNCT
dpc-3893	190	1	seneschal	seneschal	PROPN
dpc-3893	190	2	j	j	PROPN
dpc-3893	190	3	,	,	PUNCT
dpc-3893	190	4	duplaine	duplaine	ADJ
dpc-3893	190	5	a	a	PRON
dpc-3893	190	6	,	,	PUNCT
dpc-3893	190	7	maillard	maillard	ADJ
dpc-3893	190	8	h	h	NOUN
dpc-3893	190	9	,	,	PUNCT
dpc-3893	190	10	et	et	PROPN
dpc-3893	190	11	al	al	PROPN
dpc-3893	190	12	.	.	PROPN
dpc-3893	190	13	efficacy	efficacy	NOUN
dpc-3893	190	14	and	and	CCONJ
dpc-3893	190	15	safety	safety	NOUN
dpc-3893	190	16	of	of	ADP
dpc-3893	190	17	tacrolimus	tacrolimus	NOUN
dpc-3893	190	18	0.1	0.1	NUM
dpc-3893	190	19	%	%	NOUN
dpc-3893	190	20	for	for	ADP
dpc-3893	190	21	the	the	DET
dpc-3893	190	22	treatment	treatment	NOUN
dpc-3893	190	23	of	of	ADP
dpc-3893	190	24	facial	facial	ADJ
dpc-3893	190	25	vitiligo	vitiligo	NOUN
dpc-3893	190	26	:	:	PUNCT
dpc-3893	190	27	a	a	DET
dpc-3893	190	28	multicenter	multicenter	NOUN
dpc-3893	190	29	randomized	randomize	VERB
dpc-3893	190	30	,	,	PUNCT
dpc-3893	190	31	double	double	ADJ
dpc-3893	190	32	-	-	PUNCT
dpc-3893	190	33	blinded	blind	VERB
dpc-3893	190	34	,	,	PUNCT
dpc-3893	190	35	vehicle	vehicle	NOUN
dpc-3893	190	36	-	-	PUNCT
dpc-3893	190	37	controlled	control	VERB
dpc-3893	190	38	study	study	NOUN
dpc-3893	190	39	.	.	PUNCT
dpc-3893	191	1	j	j	NOUN
dpc-3893	191	2	 	 	SPACE
dpc-3893	191	3	investig	investig	NOUN
dpc-3893	191	4	dermatol	dermatol	NOUN
dpc-3893	191	5	2021;141:1728–34	2021;141:1728–34	NUM
dpc-3893	191	6	.	.	PUNCT
dpc-3893	192	1	12	12	NUM
dpc-3893	192	2	.	.	PUNCT
dpc-3893	193	1	lepe	lepe	PROPN
dpc-3893	193	2	v	v	PROPN
dpc-3893	193	3	,	,	PUNCT
dpc-3893	193	4	moncada	moncada	PROPN
dpc-3893	193	5	b	b	PROPN
dpc-3893	193	6	,	,	PUNCT
dpc-3893	193	7	castanedo	castanedo	ADJ
dpc-3893	193	8	-	-	PUNCT
dpc-3893	193	9	cazares	cazare	NOUN
dpc-3893	193	10	jp	jp	PROPN
dpc-3893	193	11	,	,	PUNCT
dpc-3893	193	12	torres	torres	PROPN
dpc-3893	193	13	-	-	PUNCT
dpc-3893	193	14	alvarez	alvarez	PROPN
dpc-3893	193	15	mb	mb	PROPN
dpc-3893	193	16	,	,	PUNCT
dpc-3893	193	17	ortiz	ortiz	PROPN
dpc-3893	193	18	ca	can	AUX
dpc-3893	193	19	,	,	PUNCT
dpc-3893	193	20	torres	torres	PROPN
dpc-3893	193	21	-	-	PUNCT
dpc-3893	193	22	rubalcava	rubalcava	PROPN
dpc-3893	193	23	ab	ab	PROPN
dpc-3893	193	24	.	.	PUNCT
dpc-3893	194	1	a	a	DET
dpc-3893	194	2	double	double	ADJ
dpc-3893	194	3	-	-	PUNCT
dpc-3893	194	4	blind	blind	ADJ
dpc-3893	194	5	randomized	randomized	ADJ
dpc-3893	194	6	trial	trial	NOUN
dpc-3893	194	7	of	of	ADP
dpc-3893	194	8	0.1	0.1	NUM
dpc-3893	194	9	%	%	NOUN
dpc-3893	194	10	tacrolimus	tacrolimus	NOUN
dpc-3893	194	11	vs	vs	ADP
dpc-3893	194	12	0.05	0.05	NUM
dpc-3893	194	13	%	%	NOUN
dpc-3893	194	14	clobetasol	clobetasol	NOUN
dpc-3893	194	15	for	for	ADP
dpc-3893	194	16	the	the	DET
dpc-3893	194	17	treatment	treatment	NOUN
dpc-3893	194	18	of	of	ADP
dpc-3893	194	19	childhood	childhood	NOUN
dpc-3893	194	20	vitiligo	vitiligo	NOUN
dpc-3893	194	21	.	.	PUNCT
dpc-3893	195	1	archives	archive	NOUN
dpc-3893	195	2	of	of	ADP
dpc-3893	195	3	dermatology	dermatology	NOUN
dpc-3893	195	4	2003;139:581–5	2003;139:581–5	NOUN
dpc-3893	195	5	.	.	PUNCT
dpc-3893	196	1	13	13	NUM
dpc-3893	196	2	.	.	PUNCT
dpc-3893	197	1	rosmarin	rosmarin	PROPN
dpc-3893	197	2	d	d	PROPN
dpc-3893	197	3	,	,	PUNCT
dpc-3893	197	4	passeron	passeron	PROPN
dpc-3893	197	5	t	t	PROPN
dpc-3893	197	6	,	,	PUNCT
dpc-3893	197	7	pandya	pandya	PROPN
dpc-3893	197	8	ag	ag	PROPN
dpc-3893	197	9	,	,	PUNCT
dpc-3893	197	10	et	et	PROPN
dpc-3893	197	11	al	al	PROPN
dpc-3893	197	12	.	.	PROPN
dpc-3893	198	1	two	two	NUM
dpc-3893	198	2	phase	phase	NOUN
dpc-3893	198	3	3	3	NUM
dpc-3893	198	4	,	,	PUNCT
dpc-3893	198	5	randomized	randomize	VERB
dpc-3893	198	6	,	,	PUNCT
dpc-3893	198	7	controlled	control	VERB
dpc-3893	198	8	trials	trial	NOUN
dpc-3893	198	9	of	of	ADP
dpc-3893	198	10	ruxolitinib	ruxolitinib	NOUN
dpc-3893	198	11	cream	cream	NOUN
dpc-3893	198	12	for	for	ADP
dpc-3893	198	13	vitiligo	vitiligo	NOUN
dpc-3893	198	14	.	.	PUNCT
dpc-3893	199	1	new	new	ADJ
dpc-3893	199	2	engl	engl	PROPN
dpc-3893	199	3	j	j	PROPN
dpc-3893	199	4	med	med	PROPN
dpc-3893	199	5	2022;387:1445–55	2022;387:1445–55	PROPN
dpc-3893	199	6	.	.	PUNCT
dpc-3893	200	1	14	14	NUM
dpc-3893	200	2	.	.	PUNCT
dpc-3893	201	1	esmat	esmat	PROPN
dpc-3893	201	2	sm	sm	PROPN
dpc-3893	201	3	,	,	PUNCT
dpc-3893	201	4	el‐mofty	el‐mofty	PROPN
dpc-3893	201	5	m	m	PROPN
dpc-3893	201	6	,	,	PUNCT
dpc-3893	201	7	rasheed	rasheed	NOUN
dpc-3893	201	8	h	h	PROPN
dpc-3893	201	9	,	,	PUNCT
dpc-3893	201	10	et	et	PROPN
dpc-3893	201	11	al	al	PROPN
dpc-3893	201	12	.	.	PROPN
dpc-3893	201	13	efficacy	efficacy	NOUN
dpc-3893	201	14	of	of	ADP
dpc-3893	201	15	narrow	narrow	ADJ
dpc-3893	201	16	band	band	NOUN
dpc-3893	201	17	uvb	uvb	ADJ
dpc-3893	201	18	with	with	ADP
dpc-3893	201	19	or	or	CCONJ
dpc-3893	201	20	without	without	ADP
dpc-3893	201	21	omp	omp	PROPN
dpc-3893	201	22	in	in	ADP
dpc-3893	201	23	stabilization	stabilization	NOUN
dpc-3893	201	24	of	of	ADP
dpc-3893	201	25	vitiligo	vitiligo	ADJ
dpc-3893	201	26	activity	activity	NOUN
dpc-3893	201	27	in	in	ADP
dpc-3893	201	28	skin	skin	NOUN
dpc-3893	201	29	photo‐types	photo‐type	NOUN
dpc-3893	201	30	(	(	PUNCT
dpc-3893	201	31	iii	iii	NOUN
dpc-3893	201	32	–	–	PUNCT
dpc-3893	201	33	v	v	NOUN
dpc-3893	201	34	):	):	PUNCT
dpc-3893	201	35	a	a	DET
dpc-3893	201	36	double‐blind	double‐blind	NOUN
dpc-3893	201	37	,	,	PUNCT
dpc-3893	201	38	randomized	randomize	VERB
dpc-3893	201	39	,	,	PUNCT
dpc-3893	201	40	placebo‐controlled	placebo‐controlle	VERB
dpc-3893	201	41	,	,	PUNCT
dpc-3893	201	42	prospective	prospective	ADJ
dpc-3893	201	43	,	,	PUNCT
dpc-3893	201	44	multicenter	multicenter	ADJ
dpc-3893	201	45	study	study	NOUN
dpc-3893	201	46	.	.	PUNCT
dpc-3893	202	1	photodermatol	photodermatol	PROPN
dpc-3893	202	2	photoimmunol	photoimmunol	NOUN
dpc-3893	202	3	photomed	photome	VERB
dpc-3893	202	4	2021	2021	NUM
dpc-3893	202	5	.	.	PUNCT
dpc-3893	203	1	15	15	NUM
dpc-3893	203	2	.	.	X
dpc-3893	203	3	esmat	esmat	PROPN
dpc-3893	203	4	s	s	PROPN
dpc-3893	203	5	,	,	PUNCT
dpc-3893	203	6	hegazy	hegazy	PROPN
dpc-3893	203	7	ra	ra	PROPN
dpc-3893	203	8	,	,	PUNCT
dpc-3893	203	9	shalaby	shalaby	PROPN
dpc-3893	203	10	s	s	PROPN
dpc-3893	203	11	,	,	PUNCT
dpc-3893	203	12	hu	hu	PROPN
dpc-3893	203	13	sc	sc	PROPN
dpc-3893	203	14	-	-	PUNCT
dpc-3893	203	15	s	s	PROPN
dpc-3893	203	16	,	,	PUNCT
dpc-3893	203	17	lan	lan	PROPN
dpc-3893	203	18	c	c	PROPN
dpc-3893	203	19	-	-	PUNCT
dpc-3893	203	20	ce	ce	PROPN
dpc-3893	203	21	.	.	PROPN
dpc-3893	203	22	phototherapy	phototherapy	NOUN
dpc-3893	203	23	and	and	CCONJ
dpc-3893	203	24	combination	combination	NOUN
dpc-3893	203	25	therapies	therapy	NOUN
dpc-3893	203	26	for	for	ADP
dpc-3893	203	27	vitiligo	vitiligo	NOUN
dpc-3893	203	28	.	.	PUNCT
dpc-3893	204	1	dermatologic	dermatologic	ADJ
dpc-3893	204	2	clinics	clinic	NOUN
dpc-3893	204	3	2017;35:171–92	2017;35:171–92	PRON
dpc-3893	204	4	.	.	PUNCT
dpc-3893	205	1	16	16	NUM
dpc-3893	205	2	.	.	PUNCT
dpc-3893	206	1	esmat	esmat	PROPN
dpc-3893	206	2	s	s	PROPN
dpc-3893	206	3	,	,	PUNCT
dpc-3893	206	4	mostafa	mostafa	PROPN
dpc-3893	206	5	w	w	PROPN
dpc-3893	206	6	,	,	PUNCT
dpc-3893	206	7	hegazy	hegazy	PROPN
dpc-3893	206	8	ra	ra	PROPN
dpc-3893	206	9	,	,	PUNCT
dpc-3893	206	10	et	et	PROPN
dpc-3893	206	11	al	al	PROPN
dpc-3893	206	12	.	.	PUNCT
dpc-3893	206	13	phototherapy	phototherapy	PROPN
dpc-3893	206	14	:	:	PUNCT
dpc-3893	206	15	the	the	DET
dpc-3893	206	16	vitiligo	vitiligo	PROPN
dpc-3893	206	17	management	management	NOUN
dpc-3893	206	18	pillar	pillar	NOUN
dpc-3893	206	19	.	.	PUNCT
dpc-3893	207	1	clin	clin	PROPN
dpc-3893	207	2	dermatol	dermatol	PROPN
dpc-3893	207	3	2016;34:594–602	2016;34:594–602	PROPN
dpc-3893	207	4	.	.	PUNCT
dpc-3893	208	1	17	17	NUM
dpc-3893	208	2	.	.	PUNCT
dpc-3893	209	1	mohammad	mohammad	PROPN
dpc-3893	209	2	tf	tf	PROPN
dpc-3893	209	3	,	,	PUNCT
dpc-3893	209	4	al	al	PROPN
dpc-3893	209	5	-	-	PROPN
dpc-3893	209	6	jamal	jamal	PROPN
dpc-3893	209	7	m	m	PROPN
dpc-3893	209	8	,	,	PUNCT
dpc-3893	209	9	hamzavi	hamzavi	PROPN
dpc-3893	209	10	ih	ih	PRON
dpc-3893	209	11	,	,	PUNCT
dpc-3893	209	12	et	et	PROPN
dpc-3893	209	13	al	al	PROPN
dpc-3893	209	14	.	.	PUNCT
dpc-3893	210	1	the	the	DET
dpc-3893	210	2	vitiligo	vitiligo	PROPN
dpc-3893	210	3	working	working	NOUN
dpc-3893	210	4	group	group	NOUN
dpc-3893	210	5	recommendations	recommendation	NOUN
dpc-3893	210	6	for	for	ADP
dpc-3893	210	7	narrowband	narrowband	PROPN
dpc-3893	210	8	ultraviolet	ultraviolet	PROPN
dpc-3893	211	1	b	b	PROPN
dpc-3893	211	2	light	light	ADJ
dpc-3893	211	3	phototherapy	phototherapy	NOUN
dpc-3893	211	4	treatment	treatment	NOUN
dpc-3893	211	5	of	of	ADP
dpc-3893	211	6	vitiligo	vitiligo	PROPN
dpc-3893	211	7	.	.	PUNCT
dpc-3893	212	1	journal	journal	PROPN
dpc-3893	212	2	of	of	ADP
dpc-3893	212	3	the	the	DET
dpc-3893	212	4	american	american	PROPN
dpc-3893	212	5	academy	academy	PROPN
dpc-3893	212	6	of	of	ADP
dpc-3893	212	7	dermatology	dermatology	NOUN
dpc-3893	212	8	2017;76:879–88	2017;76:879–88	NUM
dpc-3893	212	9	.	.	PROPN
dpc-3893	212	10	18	18	NUM
dpc-3893	212	11	.	.	PUNCT
dpc-3893	213	1	mohammad	mohammad	PROPN
dpc-3893	213	2	tf	tf	PROPN
dpc-3893	213	3	,	,	PUNCT
dpc-3893	213	4	silpa	silpa	NOUN
dpc-3893	213	5	-	-	PUNCT
dpc-3893	213	6	archa	archa	PROPN
dpc-3893	213	7	n	n	CCONJ
dpc-3893	213	8	,	,	PUNCT
dpc-3893	213	9	griffith	griffith	PROPN
dpc-3893	213	10	jl	jl	PROPN
dpc-3893	213	11	,	,	PUNCT
dpc-3893	213	12	lim	lim	PROPN
dpc-3893	213	13	hw	hw	PROPN
dpc-3893	213	14	,	,	PUNCT
dpc-3893	213	15	hamzavi	hamzavi	VERB
dpc-3893	213	16	ih	ih	PRON
dpc-3893	213	17	.	.	PUNCT
dpc-3893	214	1	home	home	NOUN
dpc-3893	214	2	phototherapy	phototherapy	NOUN
dpc-3893	214	3	in	in	ADP
dpc-3893	214	4	vitiligo	vitiligo	PROPN
dpc-3893	214	5	.	.	PUNCT
dpc-3893	215	1	photodermatology	photodermatology	NOUN
dpc-3893	215	2	,	,	PUNCT
dpc-3893	215	3	photoimmunology	photoimmunology	NOUN
dpc-3893	215	4	&	&	CCONJ
dpc-3893	215	5	photomedicine	photomedicine	PROPN
dpc-3893	215	6	2017;33:241–52	2017;33:241–52	PROPN
dpc-3893	215	7	.	.	PROPN
dpc-3893	215	8	19	19	NUM
dpc-3893	215	9	.	.	PUNCT
dpc-3893	216	1	batchelor	batchelor	PROPN
dpc-3893	216	2	jm	jm	PROPN
dpc-3893	216	3	,	,	PUNCT
dpc-3893	216	4	millington	millington	PROPN
dpc-3893	216	5	a	a	PROPN
dpc-3893	216	6	,	,	PUNCT
dpc-3893	216	7	thomas	thomas	PROPN
dpc-3893	216	8	ks	ks	PROPN
dpc-3893	216	9	,	,	PUNCT
dpc-3893	216	10	et	et	PROPN
dpc-3893	216	11	al	al	PROPN
dpc-3893	216	12	.	.	PROPN
dpc-3893	216	13	home	home	NOUN
dpc-3893	216	14	-	-	PUNCT
dpc-3893	216	15	based	base	VERB
dpc-3893	216	16	narrowband	narrowband	NOUN
dpc-3893	216	17	uvb	uvb	ADJ
dpc-3893	216	18	,	,	PUNCT
dpc-3893	216	19	topical	topical	ADJ
dpc-3893	216	20	corticosteroid	corticosteroid	NOUN
dpc-3893	216	21	or	or	CCONJ
dpc-3893	216	22	combination	combination	NOUN
dpc-3893	216	23	for	for	ADP
dpc-3893	216	24	children	child	NOUN
dpc-3893	216	25	and	and	CCONJ
dpc-3893	216	26	adults	adult	NOUN
dpc-3893	216	27	with	with	ADP
dpc-3893	216	28	vitiligo	vitiligo	NOUN
dpc-3893	216	29	:	:	PUNCT
dpc-3893	216	30	hi	hi	ADJ
dpc-3893	216	31	-	-	PUNCT
dpc-3893	216	32	light	light	NOUN
dpc-3893	216	33	vitiligo	vitiligo	VERB
dpc-3893	216	34	three	three	NUM
dpc-3893	216	35	-	-	PUNCT
dpc-3893	216	36	arm	arm	NOUN
dpc-3893	216	37	rct	rct	PROPN
dpc-3893	216	38	.	.	PROPN
dpc-3893	216	39	heal	heal	VERB
dpc-3893	216	40	technol	technol	ADJ
dpc-3893	216	41	assess	assess	NOUN
dpc-3893	216	42	2020;24:1–128	2020;24:1–128	NOUN
dpc-3893	216	43	.	.	PUNCT
dpc-3893	217	1	20	20	NUM
dpc-3893	217	2	.	.	PUNCT
dpc-3893	217	3	teulings	teuling	NOUN
dpc-3893	217	4	he	he	PRON
dpc-3893	217	5	,	,	PUNCT
dpc-3893	217	6	overkamp	overkamp	PROPN
dpc-3893	217	7	m	m	PROPN
dpc-3893	217	8	,	,	PUNCT
dpc-3893	217	9	ceylan	ceylan	PROPN
dpc-3893	217	10	e	e	PROPN
dpc-3893	217	11	,	,	PUNCT
dpc-3893	217	12	et	et	PROPN
dpc-3893	217	13	al	al	PROPN
dpc-3893	217	14	.	.	PROPN
dpc-3893	217	15	decreased	decrease	VERB
dpc-3893	217	16	risk	risk	NOUN
dpc-3893	217	17	of	of	ADP
dpc-3893	217	18	melanoma	melanoma	NOUN
dpc-3893	217	19	and	and	CCONJ
dpc-3893	217	20	nonmelanoma	nonmelanoma	ADJ
dpc-3893	217	21	skin	skin	NOUN
dpc-3893	217	22	cancer	cancer	NOUN
dpc-3893	217	23	in	in	ADP
dpc-3893	217	24	patients	patient	NOUN
dpc-3893	217	25	with	with	ADP
dpc-3893	217	26	vitiligo	vitiligo	NOUN
dpc-3893	217	27	:	:	PUNCT
dpc-3893	217	28	a	a	DET
dpc-3893	217	29	survey	survey	NOUN
dpc-3893	217	30	among	among	ADP
dpc-3893	217	31	1307	1307	NUM
dpc-3893	217	32	patients	patient	NOUN
dpc-3893	217	33	and	and	CCONJ
dpc-3893	217	34	their	their	PRON
dpc-3893	217	35	partners	partner	NOUN
dpc-3893	217	36	.	.	PUNCT
dpc-3893	218	1	british	british	ADJ
dpc-3893	218	2	journal	journal	PROPN
dpc-3893	218	3	of	of	ADP
dpc-3893	218	4	dermatology	dermatology	NOUN
dpc-3893	218	5	2012;168:162–71doi:10.1111	2012;168:162–71doi:10.1111	NUM
dpc-3893	218	6	/	/	SYM
dpc-3893	218	7	bjd.12111	bjd.12111	X
dpc-3893	218	8	.	.	PUNCT